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INTRODUCTION 
Few areas in medicine can equal the rapid 
proliferation of information that has occurred and 
continues to occw;. in •. the area of human reproduc­
tion. The progress in our understanding of the 
underlying mechanisms which control the human 
female reproductive system has led to an ever­
increasing refinement in the definition of pathologic 
states and the development of specific, effective 
therapeutic agents for some of these. It is clear 
that not all is yet known and that there is need 
for repetitive reassessment of our knowledge in order 
to keep abreast of these rapid discoveries. Preg­
nancy, once achieved, is subject to yet another sys­
tem of hazards about which a great deal has been 
learned. Both maternal and fetal diseases have 
become better understood through more refined 
diagnostic methods. More specific and successful 
methods of management have been designed. The 
improvement in the outcome of these high-risk 
pregnancies can now be demonstrated, but it does 
require up-to-date knowledge and skills on the part 
of the physician and a constant effort against the 
social and economic obstacles which prevent optimal 
care. With the occurrence of malignant change in 
the reproductive organs, a new set of hazards is ex­
perienced. The admirable degree of international 
cooperation among gynecologic oncologists with 
common staging systems and controlled therapeutic 
studies has led to rapid improvement in cure 
4 
rates of most, but not all, gynecologic malignancies. 
Periodic review of present therapeutic modalities, 
newer (and generally more conservative) modalities, 
and the accumulated epidemiologic data is of im­
portance in keeping us oriented. Understanding of 
gynecologic malignancies has contributed much to 
our understanding of many similar malignancies. 
Not all the changes which are occurring can 
be reviewed within the scope of this conference. 
However, we are indeed fortunate to be able to 
learn the most current information from recog­
nized leaders in their specific field. We are most 
grateful to our guest lecturers who interrupted their 
busy and productive lives to come to Richmond 
to share their knowledge with us and to our MCV 
faculty for their participation. 
Our special thanks to Dr. Saul B. Gusberg 
who was the 46th McGuire Lecturer and to Dr. 
Robert A. Munsick, our second H. Hudnall Ware, 
Jr. Visiting Professor. We would also like to recog­
nize the H. Hudnall Ware, Jr. Society and its 
president. Dr. Louis Keffer, for their sponsorship 
and participation. 
LEO J. DUNN, M.D. 
Professor and Chairman 
Department of Obstetrics and Gynecology 
Medical College of Virginia 
Virginia Commonwealth University 
Modern Management of Diabetic Pregnancies* 
ELSIE R. CARRINGTON, M.D. 
Professor and Chairman, Department of Obstetrics and Gynecology. 
Medical College of Pennsylvania, Philadelphia. Pennsylvania 
On a broad national basis. it should be quite 
possible to substantially reduce maternal morbidity 
and the disproportionately high numbers of perinatal 
losses associated with diabetic pregnancies. Nation­
wide, the overall perinatal mortality rate for this 
group is approximately 20%. which is at least double 
that incurred in centers where intensive care facilities 
and personnel are available. and consistent, well­
coordinated care by the health team is provided. 
Although the prognosis for fetal survival is less 
favorable with advances in severity of the diabetic 
state. there is a significant risk even during the 
mildest stage of the disease. Careful prospective 
studies. notably those of O'Sullivan and his group. 
have demonstrated that gestational diabetics have a 
higher than normal perinatal mortality. Prevention 
begins with diagnosis. 
Detection. Ideally, a two-hour postprandial 
screening of blood sugar following a 100 g 
carbohydrate-equivalent breakfast should be a stan­
dard prenatal laboratory test. In practicality. all 
patients with a poor obstetric history, previous 
perinatal losses, large babies, a family history of 
diabetes. glycosuria, or significant obesity are can­
didates for a glucose tolerance test. Using these 
criteria, we subjected 3,340 prenatal patients to the 
three-hour glucose tolerance test following a 100 g 
glucose load, and 540 showed abnormal responses. 
The yield of positives, therefore, was I in 6.3 suspects, 
and the overall incidence of gestational diabetes in 
this Philadelphia population was 1.18%. Criteria used 
are as follows: fasting = 90 mg %: I hour = 165 mg 
• The following summarizes 1he main points of a leclure 
presented by Dr. Carringlon al the 46th Annual McGuire Leclure 
Series. December 5. 1974, al the Medical College of Virginia. Rich­
mond. 
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%: 2 hour = 145 mg %: 3 hour = 125 mg%. Glucose 
tolerance is impaired if two or more of these values 
are equaled or exceeded. The test is performed on 
whole blood using the Somogyi method or 
autoanalyzer (Hoffman) method. If plasma or serum 
is used. 10 mg % should be added to each of the 
values. The importance of a very large screening 
program was shown in the prospective study con­
ducted by O'Sullivan and his group who found that 
screening is particularly important in the obese, 
older-age patient. Perinatal mortality was 1.5% for 
normal control patients and 6.4% for those with 
gestational diabetes. The increase in perinatal loss 
was strikingly evident in gestational diabetic mothers 
25 years of age or older, with the risk further in­
creased by obesity. 
Metabolic Control. How strict should this be'1 
These patients are ketosis prone. Ketosis is one of the 
most lethal events for the fetus. but one of the most 
preventable complications for the mother. The in­
cidence of intrauterine fetal death is greatly increased 
in pregnancies complicated by pre-coma maternal 
acidosis. Of further concern is the fact that the 
National Collaborative Study reveals a significant 
relationship between maternal ketonuria and central 
nervous system defects or deficiencies in the off­
spring. Neither insulin treatment nor hypoglycemia 
shows a positive association. For these reasons the 
patient should be kept as nearly normoglycemic as 
possible and free of ketonuria even at the expense 
of an occasional episode of hypoglycemia which is 
readily controlled. 
Many, but not all, gestational diabetics can be 
maintained on diet alone. The response to diet is 
determined on the basis of a two-hour postprandial 
blood sugar obtained at two-week intervals. If the 
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two-hour value on diet cannot be maintained below 
160 mg%, the patient needs insulin, and for the pur­
pose of management of the pregnancy such patients 
should be considered in the insulin-dependent cate­
gory. 
Is there any advantage in treating all gestational 
diabetics with low-dose insulin? Several groups in this 
country and abroad have compared treated and un­
treated cases. Apart from slight reduction in over­
sized infants, other advantages are not yet sufficiently 
clear-cut to warrant recommending this approach. 
Oral hypoglycemic agents should not be used in 
pregnancy. In contrast to insulin, the sulfonyl ureas 
pass the placental barrier readily. Neonatal hepatic 
function is relatively immature, and the newborn 
metabolizes these drugs poorly. Intractable 
hypoglycemia persisting as long as the eleventh day 
of life, and in some instances requiring exchange 
transfusion, have been reported, particularly in rela­
tion to long-acting preparations such as chlor­
propamide. The biguanides which raise the blood lac­
tate level may accentuate the tendency to maternal 
ketoacidosis and are contraindicated during pregnan­
cy. 
The anti-insulin effects of pregnancy usually 
cause significant changes in insulin needs after the 
20 th week of gestation. The rise in requirement is 
sometimes precipitous about the 24th to 26th week. 
Both the patient and the physician should be on the 
lookout for these changes. In our patients, 75% needed 
a mean of about 60% more insulin. Twenty-three 
percent showed only minor increase in insulin 
requirement. Only an occasional patient showed 
reduction in insulin need. 
One of the poorly understood problems has to 
do with remission, which may occur particularly in 
the early stages of diabetes. How does one handle the 
patient who states that she had an abnormal glucose 
tolerance test with her previous pregnancy and was 
treated accordingly, but the glucose tolerance test in 
the present pregnancy is normal? While it is the rule 
that the diabetic state will progress, remissions do oc­
cur. We have encountered this phenomenon in a 
number of gestational diabetics and in one case of 
juvenile diabetes. Since the adverse ef
f
ect upon the 
fetus can occur al any stage including the prediabetic 
period, it is important to accept the reality of remis­
sion and to avoid the temptation to ascribe its oc­
currence to faulty initial diagnosis. 
Most diabetics have some degree of hydramnios, 
excessive in approximately 10% of cases. The com-
mon practice of prophylactic use of diuretic and 
rigid salt restriction may do more harm than good. 
Thiazides are useful only in otherwise uncompli­
cated fluid retention. If administered alternately 
three days on and three days off, these drugs will 
often reverse simple fluid shifts without disturbing 
electrolyte balance, but they are ineffectual for re­
versal of toxemia or hydramnios. Hospitalization 
is necessary if these conditions develop. Asympto­
matic bacteriuria is found in about 12 or 13% of 
diabetic pregnancies, or approximately twice the 
overall incidence, and should be treated when 
found. 
Prenatal Monitoring. The ability to predict in­
trauterine fetal deaths in diabetic pregnancies on 
clinical evidence alone has limitations. A reliable 
method for assessing intrauterine fetal welfare should 
be available in every diabetic pregnancy. Although 
no single test is capable of detecting all types of 
malfunctions that affect the fetus, the urine estriol 
test is, in our experience, indispensable. The fact 
that estriol production requires a fetal as well as a 
placental component is an obvious advantage. The 
types of cases in which estriol values may be mis­
leading are small in number and can usually be 
readily identified. These are mainly cases in which 
renal function is markedly reduced and renal clear­
ance of estriol diminished. 
Although the majority of patients with mild 
diabetes can be maintained free of complications and 
await labor at term, some cannot. Fetal deaths do oc­
cur in the virtually asymptomatic, well-controlled 
gestational diabetic pregnancy. In these cases, estriol 
determinations have proved to be of great value in 
identifying the fetus in jeopardy who should be 
delivered and, on the other hand, in providing 
reassurance and safe conduct through the natural 
course of pregnancy when estriol values remain in the 
normal range. 
Recent recommendations have been made to 
apply the same principles to pregnancies complicated 
by overt diabetes. While it is feasible to individualize 
and extend the timing of delivery to the 38th week 
or even beyond in many cases of B and C insulin­
dependent diabetics, those with advanced disease are 
poor candidates for this approach, even with frequent 
monitoring. From a practical point of view, and 
purely on clinical grounds, pregnancy in a patient 
with angiopathy, retinopathy, or nephropathy can 
rarely be carried beyond the 37th week, and all too 
often the pregnancy has to be terminated before that 
CARRINGTON: MODERN MANAGEMENT OF DIABETIC PREGNANCIES 7 
optimal time in the interest of the mother or baby or 
both. The suddenness with which serious changes or 
events can take place in these patients and the fact 
that methods for determining fetal maturity are 
available (particularly the lecithin/sphingomyelin 
ratio and the creatinine concentration) offset the 
possible advantages of attempting to extend the 
gestational period for Classes D. E. and F diabetics 
beyond 37 weeks. 
The infant of a diabetic mother is at risk from 
the moment of birth. Respiratory distress is the 
greatest threat. It is most directly related to 
prematurity and accentuated in diabetes. While tests 
for fetal maturity should make iatrogenic prematuri­
ty preventable, early delivery will continue to be 
necessary in selected cases to avoid intrauterine fetal 
death or damage. The neonatologist experienced in 
dealing with respiratory pathophysiology who can 
initiate treatment within minutes after birth, and a 
neonatal intensive care unit capable of providing 
clinical and laboratory support services on a 24-
hour-a-day basis offer the best chance for intact 
survival. 
In principle. the problems of diabetic pregnan­
cies do not differ from the problems of at least two­
thirds of all high-risk pregnancies, and in this respect, 
they serve as a prototype for centralized perinatal 
care. The demands in terms of medical and 
paramedical manpower. the high cost of services and 
facilities comprising the perinatal center, and the con­
cern for quality of life will surely require revision of 
the current health care delivery system. Consolida­
tion of scarce resources in centers. whether teaching 
or community hospitals. capable of providing 
specialized care for the high-risk mother and new­
born is the logical approach. 
The Endocrinologic Evaluation of 
Amenorrhea* ** 
CHARLES B. HAMMOND, M.D., R. HERBERT WIEBE, M.D .. 
LEE TYREY, PH.D., DAVID W. SCHOMBERG, PH.D. 
Division of Endocrinology and lnfenility, Department of Obstetrics and 
Gynecology, Duke University Medical Center, Durham, North Carolina 
Introduction. The purpose of this paper is to 
review the endocrinologic evaluation of 58 patients 
who presented to our institution this past year with a 
chief complaint of absent or irregular menses. The 
primary goal for presenting these patients is to review 
the results of several newer studies as well as older 
and more classical studies which are useful in the 
differential diagnosis of amenorrhea. Such newer 
studies not only take advantage of the more current 
knowledge of the ovulatory process but also utilize 
recently developed and highly sensitive techniques or 
hormonal assay. It is hoped that this will provide the 
reader with some suggestions for a current and 
efficient method to evaluate the several causes or 
amenorrhea. 
Materials and Methods. Amenorrhea is usually 
categorized as being either primary or secondary. and 
the patient's age or duration of absent menses varies 
among the several definitions available. For the pur­
pose of this paper the following definitions will be 
utilized: 
Primary Amenorrhea. Failure to have initiated 
menstrual bleeding by age 18. 
Secondary Amenorrhea. Cessation of previously 
established menses for an interval of more than one 
year. 
0/igomenorrhea. Spontaneous, irregular menses 
* Presented by Dr. Hammond al the 46th Annual McGuire 
Lecture Series. December 5. 1974. al the Medical College of 
Virginia, Richmond. 
** Supported by a grant (RR-30) rrom the General Clinical 
Research Ccnlers Progr..im of the Division of Research Resources. 
National Institute or Health. 
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occurring at intervals of not less than three months. 
Fifty-eight patients were studied and were divid­
ed into three major diagnostic categories according to 
their presenting menstrual patterns. Eight patients 
had primary amenorrhea, forty-six had secondary 
amenorrhea. and four patients had oligomenorrhea. 
Other patients with demonstrable uterine causes of 
amenorrhea are excluded from this study. This in­
cluded patients with Asherman's syndrome, miil­
lerian abnormalities in which no uterus was pres­
ent. and testicular-feminization patients. Thus, all 
patients included had uteri capable of normal 
menstruation, and this was evidenced by proges­
terone-induced withdrawal bleeding, endometrial bi­
opsy, estrogen-progesterone withdrawal bleeding, 
and/or hysterosalpingogram. Patients with easily diag­
nosable abnormalities of thyroid or adrenal function 
also are not included, as early outpatient studies usually 
revealed the etiology of their amenorrhea and ap­
propriate therapy resulted in prompt return of menstrual 
function. For these reasons one can not draw valid 
incidence frequencies from this referral-practice popula­
tion of 58 amenorrheic patients. 
S1udies Performed. All 58 patients were 
hospitalized on the Clinical Research Ward of our 
institution and underwent study. Tests included 
a thorough general and endocrine history, com­
plete physical and pelvic examination, Papanicolaou 
smear. vaginal cytologic maturation index. complete 
blood count. urinalysis. Chem- I 8. anteroposterior 
(AP) and lateral skull x-rays. chest x-ray. and visual 
fields by perimeter. 
All 58 patients also underwent a series or 
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baseline and dynamic hormonal testing. Serum total 
estrogen (I). progesterone (2), follicle stimulating 
hormone (FSH) (3). luteinizing hormone (LH) (4), 
I and growth hormone (5) were all performed in 
duplicate by standard radioimmunoassay techniques. 
Serum prolactin was initially done in the labora­
tory or Dr. Henry Friesen and later by Dr. Stuart 
Handwerger, both using radioimmunoassay (6). 
Serum T, and T3 Uptake were done by standard 
techniques, as were urinary 17-hydroxycorlicoids and 
17-ketosteroids. 
All patients also underwent the following three 
dynamic tests of pituitary function: 
I. Hypoglycemia was induced by the intra­
venous administration of 0.1 units insulin per 
kilogram with blood glucose and human growth hor­
mone (radioimmunoassay) determined at intervals 
over 90 minutes. Blood glucose had to achieve at least 
50% reduction from fasting levels to be considered an 
adequate stimulus for the release of growth hormone. 
A positive growth hormone response to insulin­
induced hypoglycemia consisted of a peak value or 
growth hormone greater than IO ng/ml (7). 
2. Control 24-hour urine collections were ob­
tained for 17-hydroxycorticoids ( 170H) and 17-
ketosteroids ( I 7KS). If normal hydroxycorticoids 
were present. the patient was then given 
Metopirone". 750 mg orally every 4 hours for 6 
doses. After the last dose of Metopirone•. another 
24-hour urine collection was made. A normal re­
sponse of pituitary ACTH was considered present 
if the levels of 17-hydroxycorticoids doubled (8). 
3. The ability to release gonadotropins was 
tested with LH-FSH Releasing Hormone. Baseline 
FSH and LH were determined. then the patients 
received 100 µg SC of A Y 24031, Ayerst Labora­
tories LH-FSH Releasing Hormone. Blood samples 
were then taken at frequent intervals over a period 
of 6 hours, and duplicate samples were assayed by 
radioimmunoassay for FSH and LH. Serum total 
estrogens were determined by radioimmunoassay on 
the control and 6-hours samples. Currently we are 
evaluating a variety of response parameters. and we 
realize that our own criteria for a positive response 
may be altered. However, in the interim. a positive 
response to LH-FSH Releasing Hormone was con­
sidered present if both serum LH rose by more than 
fourfold over baseline and serum FSH at least 
doubled (9). 
Other Studies. As patients were evaluated by the 
techniques listed previously, many were found to 
have significant abnormalities which required further 
investigation. Such studies included: 
Patients with prolactin excess (on duplicate 
samples) usually underwent further testing of prolac­
tin kinetics with L-dopa, chlorpromazine, water load, 
and other studies. If the excess secretion was not 
readily explainable. then sella turcica tomography 
and pneumoencephalography were usually per­
formed. 
Evidence or clinical androgen excess or signifi­
cant laboratory documentation of this usually led to 
determination of serum testosterone, urinary 
pregnanetriol. and appropriate dexamethasone sup­
pression. If an ovarian source was presumed, then 
laparoscopy and ovarian biopsy were carried out. 
Elevated 17-hydroxycorticoids led to the deter­
mination of plasma cortisol and dexamethasone sup­
pression. with pituitary evaluation if pituitary tumor 
was suspected. 
Abnormal thyroid function was evaluated by 
traditional methodology. 
Patients who had stigmata of gonadal dysgene­
sis. or primary amenorrhea which seemed of gonadal 
origin (such as evidenced by elevated gonadotropins), 
were then evaluated by buccal smear and karyotype 
of peripheral leukocytes. If there was evidence or 
signif-icant early estrogen production or a "Y" 
chromosome on karyotype. then laparoscopy and 
gonadal biopsy with both histopathologic study and 
gonadal karyotype were done. Gonads with "Y" 
chromosome were surgically removed. 
If patients had abnormal skull x-rays or signifi­
cant endocrinologic evidence of hypopituitarism or 
pituitary tumor. then tomograms of the sella turcica, 
pneumoencephalography. and/or carotid arteriography 
were performed. 
Once a diagnosis was achieved. appropriate 
therapy was carried out. No patient suffered any 
significant side effects from any of these diagnostic 
studies. 
Results. After these 58 patients had completed 
the previously listed diagnostic studies. a final 
diagnosis was assigned. The tables which follow 
(Tables I. 2. 3) are each arranged with patients 
grouped by these final diagnoses and the results 
of the various diagnostic tests listed below. In this 
fashion one can not only study the results of the 
several tests performed in patients with a particular 
cause of amenorrhea but also evaluate how a specific 
test may provide useful data in the several groups of 
patient diagnoses. 
IO 
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TABLE I 
Primary Amenorrhea 
( 8 Patients) 
Constitutional Hypothalamic ?Congcnit..tl Gonadal 
Diagnosis Delay Cause Abscncc LH Dysgenesis 
(No.) (3) (2) (2) (I) 
Family Hx. + -
Estrogen I J sl. I I 
FSH-LH FSH-Normal FSH-Normal FSH-Normal 
LH-sl. I LH-sl. I LH-sl. I II 
HGH. Prolactin. 
170H. 17KS. - - - -
Thyroid 
LRH Test FSH + FSH + FSH + FSH + 
LH + LH + LH - LH + 
lnsulin-HGH + 
Metopironek + 
+ positive response. or normal test result. 
- negative response. or reduced test result. 
(See lex! for details.) 
Primary Amenorrhea (Table I). Eight patients 
presented with primary amenorrhea. Three patients 
were felt to have constitutional delay of menarche. 
Family history was positive in all three patients, and. 
while all had had a sequential development of secon­
dary sex characteristics. all had reduced estrogen 
levels. Levels of FSH were normal and LH levels 
were minimally elevated in all three patients. Baseline 
testing of other hormones was normal. There was a 
significant response in all patients to LH Releas­
ing Hormone, Insulin-Growth Hormone, and Met­
opirone®. The patients' ages were 18, 19, and 23 
years. All have subsequently begun spontaneous 
menses. 
Similar findings to those mentioned in the 
previous category were present in the testing of two 
patients thought to have "hypothalamic" primary 
amenorrhea. except there was no family history of 
delayed menarche. 
Two patients had low baseline serum LH and 
failed to elevate LH in response to LH-Releasing 
Hormone on either of two occasions. This suggested 
lo us a reduced ability to produce, or release, or a 
congenital diminution in LH. 
Finally, one patient had Turner's syndrome 
(gonadal dysgenesis) which was proven by karyotype. 
Serum FSH was quite high, but there still existed a 
capacity of the pituitary to increase gonadotropin 
release when LH-Releasing Hormone was given. 
+ 
+ 
+ + 
+ + 
Secondary Amenorrhea-Organic (Table 2). Six­
teen patients presented with secondary amenorrhea 
which was finally shown to be of an organic etiology. 
Four patients had pituitary tumors; one, a 
patient with a microadenoma and hyperprolac­
tinemia. one with clinical signs of acromegaly. Three 
of the four patients had abnormal skull x-rays and 
reduced estrogen production. Two patients had 
significantly low gonadotropin values. Baseline hor­
monal testing revealed an elevation of growth hor­
mone in the patient with acromegaly. Other baseline 
testing was normal. Two of the four patients failed to 
have an adequate response by LH (one borderline, 
however) while two had a positive response of FSH 
to LH-Releasing Hormone. One of the four patients 
had a negative growth hormone test. All had surgical­
ly proven lesions. 
Two patients had craniopharyngiomas. Both 
had positive skull x-rays and decreased estrogen and 
gonadotropins. One patient had reduced baseline 17-
hydroxycorticoids. One patient had a modest 
response to LH-Releasing Hormone while the other 
had no response. Neither patient responded to 
lnsulin-HGH testing. Metopirone® testing was not 
done in one patient. but ACTH testing was normal. 
Two patients had the "empty sella" syndrome. 
Again. skull x-rays were abnormal in both patients 
and estrogen and gonadotropins were low. Other 
baseline hormonal testing was normal. Both patients 
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responded to Insulin-HG H and Metopirone' '. but 
one patient responded poorly to LH-Releasing 
Hormone. Both patients had this diagnosis con­
firmed by pneumoencephalography. 
Two patients had Sheehan's syndrome with 
postpartum pituitary necrosis. One patient was 
clinically panhypopituitary. finding conf-irmed by low 
test results of estrogen, gonadotropins. thyroid, and 
adrenal function. Neither patient responded positive­
ly with both LH and FSH to LH-Releasing Hormone 
or Insulin-HGH. Metopirone• testing was not per­
formed when low serum cortisols were detected. 
Adrenal response to ACTH was normal. 
Four patients had clinical signs of androgen ex­
cess with significant hirsutism. Clinical estrogeniza­
tion was good in all four. but, while ba:;eline FSH 
was normal, the baseline LH was mildly elevated in 
all. Laboratory evidence of excess androgen was pres­
ent in all four patients and was reflected by elevated 
17-ketosteroids. Serum testosterone was elevated in 
two patients with Stein-Leventhal syndrome. and 
pregnanetriols were elevated in the other two patients 
who were felt to have adult-onset adrenogenital syn­
drome. In all four patients there was a normal 
response of FSH to LH-Releasing Hormone, but an 
impaired LH response. Other testing was normal. 
There were l wo other patients with organic 
causes of secondary amenorrhea, one with 
hypothyroidism and one with premature ovarian 
failure. Test n::sults are as listed. 
Secondary A 111enorrhea-Functional (Table 3 ). 
Thirty patients had secondary amenorrhea which was 
felt to be of functional etiology. Patients are divided 
into diagnoses of anorexia nervosa (4 patients) and 
"hypothalamic" causes (26 patients). This latter large 
group is subdivided into patients who had rapid 
weight loss or gain. stable weight. or had developed 
amenorrhea after utilizing oral contraceptives. Skull 
x-rays and physical examinations were negative ex­
cept for that of weight change. and for four patients 
who had galactorrhea. 
All patients with anorexia nervosa and 
hypoestrogenism had decreased gonadotropins. 
Thyroid function was reduced slightly in two 
TABLE 2 
Secondarv Amenorrhea-Organic 0
( 16 Patients) 
PituitcJry Cranio- ""Empty 
. . 
Shct!han·:-. Androgen 
Diagnosis Tumor pharyngioma Sella s� ndrvtllt! Exct:ss 
(No.) (4) (2) (2) (2) (4) 
P. Exam Acromegaly V. Fields ( 11 - Hvpopit. (I) Hirsutism (4) 
(I) 
Galactorrhea 
(I) 
Skull x-ray +(3) + + -
Estrogen I (31 I ! I 
FSH-LH ! (2) I Normal I FSH Normal 
LH I (4) 
HGH. Pro- HGHJ (II 170HJ (II Normal 170H It Ii J 17KS (41 
lactin, 170H. Pro lac- Thyroid J ( 11 J Tcstos. (2) 
I 7KS. Thyroid tin j ( 11 j !'Trio! (21 
LRH Test FSH +2 -(I) sl. I (II - FSH+ 
LH +2 LH-
lnsulin-HGH (Ii + (II + 
M e1opi rone� + - + - + 
Others: 
Hypothyroid ( 1 )-Galactorrhea: decreased estrogen. FSH. LH. thyroid :-.llldic�. 
Other testing normal. 
Prem..iture Ovarian Failure ( I )-Decreased estrogen: elevated �SH and LH. 
Other testing normal. 
+ positive response. or normal test result. 
- negative response. or reduced test result. 
(Sec text for details.) 
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TABLE 3 
Secondary Amenorrhea-Functional 
( 30 Patients) 
Anorexia 
"HYPOTHALAMIC CAUSES" (26) 
Diagnosis Nervosa Rapid wgt. Rapid wgt. Stable wgt. 
"Post Pill" Group Total 
(No.) (4) Loss(4) Gain (3) ( 15) 
(4) (26) 
Skull x-ray -
- Galactorrhea Galactorrhea 
P. Exam (.l) (
I) (4) 
Estrogen ! j(I) Normal (4) 
(2) J (7) 
FSH-LH J J (3) J (2) ,l.j (2) J (2
) sLJ (2) 
J (7) 
HGH. Pro- Thyroid sl. Normal Normal Thyroid sl. Prolactin Thyroid! (3) 
lactin. 170H. l (2) 
17KS. thyroid 
LRH Test -(3) -(3) 
lnsulin-HGH + -(I) 
Metopirone" + + 
+ positive response. or normal test result. 
- negative response. or reduced test result. 
patients. Three of the four patients failed lo respond 
to LH-Releasing Hormone, but all patients had nor­
mal responses lo insulin by growth hormone and to 
Metopirone•. 
The four patients with rapid weight loss. but not 
anorexia nervosa. showed better estrogenization. but 
low gonadotropins also. Similar poor responsiveness 
to LH-Releasing Hormone was present. 
A greater percentage of patients who had rapid 
weight gain had normal estrogenization. baseline 
gonadotropins. and normal LH-Releasing Hormone 
response. 
Patients with stable weight who were felt lo have 
hypothalamic amenorrhea were basically normal in 
estrogenization and baseline gonadotropins. All 
patients had at least some response lo LH-Releasing 
Hormone, and five had excessive responses. Patients 
who developed amenorrhea after using oral con­
traceptives were similar. 
The 26 patients with hypothalamic amenorrhea, 
as a group, were better estrogenized, had more nor­
mal gonadotropins, and responded more normally or 
excessively to LH-Releasing Hormone than did <he 
patients with anorexia nervosa or patients with 
organic causes of secondary amenorrhea. 
0/igomenorrhea. Four patients had oligo­
menorrhea, two with evidence of ovarian androgen 
excess. Baseline estrogen, gonadotropins, and 
l (3) 1(1) Prolactin I (I) 
-(IJ I +(5) (IJ ++(5) 
+ 
+ 
sl.J (6) sl.j(IJ sl. J (7) 
- (5) 
+ + (I) 
+ + + 
other hormone testing were normal except for one 
patient who was hypothyroid and two hirsute 
patients in whom there were elevated 17-ketosteroids 
and serum testosterone. All four patients had positive 
responses to LH-Releasing Hormone. although in 
two of these patients the response of LH was 
borderline. All patients had normal responses to 
lnsulin-HGH and Metopirone®. 
Summary of Studies. In an attempt to summarize 
these diagnostic studies, one can draw the following 
conclusions from this group of 58 amenorrheic 
women: 
Skull x-rays are very useful, if positive. 
Physical examination is useful when obvious 
signs of endocrinopathy are present, including 
acromegaly. hypopituitarism. galactorrhea. or signs 
of androgen excess. Negative findings do not exclude 
significant organic pathology, however. Findings 
suggesting deficiency of a "target gland" (for 
example, adrenal, thyroid) may be reflections of 
pituitary-hypothalamic dysfunction rather than peri­
pheral gland abnormality. 
Patients with organic causes of amenorrhea are 
more likely lo have clinical hypoestrogenism. and it 
will lend lo be more severe than in patients with 
"functional" or nonorganic causes. The exception is 
anorexia nervosa. certainly a severe functional dis­
order. 
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FI
G
UR E I 
AMENORRHEA 
OUTPATIENT EVALUATION 
Thyroid 
Adrenal 
H,. Physical and Pelvic Exams 
Maturation Index 
Endometrial Biopsy 
CBC. Urinalysis. Chem. 
Skull ,-ray 
170H. 17KS 
FSH 
Thyroid T,. T, 
Progesterone;: Tcsl 
Visual Fields 
Andrugcn 
1-a i lclJ 
Ovary 
l l l 
SUSPECTED 
HYPOPtTUlTARISM 
Baseline serum FSH is of use in identifying 
gonadal failure. or dysgenesis. when FSH is very 
high. 1 n problems of androgen excess and functional 
causes of primary amenorrhea. LH seems likely to be: 
slightly elevated with FSH normal. Gonadotropins 
are low in patients both with central organic causes 
and with the more severe functional causes of this 
problem. 
Baseline measurements of growth hormone. 
prolactin. 17-hydroxycorticoids and 17-ketosteroids. 
and thyroid hormone all are of great use if ab­
normal, but usually will require further evaluation. 
Testing with LH-Releasing Hormone does 
provide useful information. Patients with organic 
causes of amenorrhea, other than gonadal failure or 
androgen excess. were more likely to respond poorly 
to LH-Releasing Hormone: however. a signiticant 
proportion of these patients showed some response: 
with regard to LH, or FSH, or both gonadotropins. 
Patients with functional disorders more likely had 
normal or excessive response to LH-Releasing Hor­
mone while those classified as having more severe 
functional disorders responded very poorly. Growth 
hormone testing with insulin and Metopirone® test­
ing were of relatively little diagnostic aid unless a 
major organic etiology was present; an etiology 
likely demonstrable on skull x-rays. clinical ex­
amination. or in patients with more severe ab­
normalities in baseline hormonal testing. 
We would again emphasize that these are only 
!rends in the results of diagnostic studies in patients 
who present with amenorrhea. Larger group studies 
are needed to evaluate the full statistical significance 
of these data. We would also again emphasize the 
need for a thoughtful. individualized. sequential 
evaluation of each patient who presents. 
Comment. To reach the goal of individualization 
in the evaluation of the amenorrheic patient we 
suggest several possibilities: 
Figure I illustrates what we consider an ade­
quate screening study for the amenorrheic patient 
which usually can be done in the outpatient setting. 
Based on these results. and the clinical tindings pres­
ent. one can categorize problems under thyroid, 
adrenal. ovarian androgen. or gonadal failure for 
further studies which can usually be done in the out-
I'
G
T
E
i 
SUSPECTED HYPOPITUITARISM 
l l l 
INPATIENT STUDY 
Baseline: FSH, LH. Prolactin. Estrogen. Growth Hormone 
Metopirune" Test (") 
Insulin-Induced Hypoglycemia Growth Hormone Test('') 
LH-Releasing Hormone Test (A Y 24031) 
l l l 
"SUSPICIOUS" 
"Fundiunal" 
Follow-up 
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.. SUSPICIOUS" HYPOPITUITARISl\1 
l l l 
2ND INPATIENT STUDY 
If Prolactin-L-Dopa test: Chlorprom,.11inc tc:-.l. \Vatc.:r load 
Pneu moenceph�1 log ram 
Carotid Arteriogram 
THERAPY 
(Medical. Surgical. Irradiation) 
patient setting. Some 
hypopituitarism and 
further study. 
patients will have suspected 
require hospitalization for 
Patients with the problem of suspected hypo­
pituitarism should undergo further testing (Fig. 
2) as evidenced by the preliminary studies. which 
should at least include baseline hormonal testing and 
testing with LH-Releasing Hormone. Growth hor­
mone testing with insulin and/or Metopirone" 
testing may be indicated. but this must be individ­
ualized. Patients who are felt to have "functional" 
disorders causing amenorrhea are begun on appro­
priate therapy or follow-up, while patients who are 
strongly suspected of hypopituitarism usually are 
studied further. 
Further studies (Fig. 3) include tests such as 
prolactin kinetics. pneumoencephalogram. and 
possibly arteriogram. If pituitary tumor. cranio­
pharygioma. or other etiology of hypopituitarism is 
found. then appropriate medical. surgical. or irradia­
tional therapy is initiated. 
In this fashion we have tried to present to you 
the summation of data in 58 patients who presented 
with amenorrhea. and the endocrinologic testing 
results that have led to the <::stablishment of a 
diagnosis. Again. it should be stressed that a 
systematic. individualized work-up is mandatory for 
the adequate endocrinologic work-up of the 
amenorrheic patient. 
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Amenorrhea Due to Defects 1n Steroid 
Biosynthesis* 
H. OLIVER WILLIAMSON. M.D. AND RAJESH S. MATHUR. PH.D. 
Depar1ment of Obstetrics and Gynecology, Medical University of South Carolina, 
Charleston. South Carolina 
Amenorrhea as the first manifestation of a 
steroid biosynthetic defect is rather unusual. The 
common forms of congenital adrenal hyperplasia are 
classic examples of steroid biosynthetic defects. Yet 
in genotypic females. this disorder is usually evident 
from birth because of virilization. Effective treatment 
usually ensues and amenorrhea is only a problem 
when control is inadequate. However. there are in­
dividuals whose disorder will be manifest for the tirst 
time in the postnatal or adult period. In addition. 
multiple other steroid defects have now been clearly 
delineated. Many of these individuals will have 
amenorrhea, virilization. or sexual ambiguities as 
part of the clinical picture. This paper will describe 
some of the more clearly delineated steroidal bio­
synthetic defects. Also, the clinical management or 
patients with postnatal onset of 21-hydroxylase defi­
ciency form of congenital adrenal hyperplasia will 
be discussed. 
Steroidogenesis. One can better appreciate the 
biochemical defects and clinical manifestations of 
these various steroid defects by having a rudimentary 
knowledge of the basic steroid pathways involved. To 
pinpoint the individual defects, it is helpful to recall 
the numbering sequen..:e of the carbon atoms of the 
steroid molecule as shown in Figure I. For the pur­
poses of this discussion, one can consider cholesterol 
as the basic substance from which steroids are de­
rived. It is at the point of its conversion to pregnenolone 
that tropic hormones have their effect; that is, ACTH 
• Presented by Dr. Williamson al the 46th Annual McGuire 
Lecture Series. December 5. 1974. al the Medical College or 
Virginia. Richmond. 
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for the adrenal cortex, and the gonadotropins for the 
gonads (Fig. 2). When circulating levels of glucocor­
ticoids or sex steroids reach sufficient levels for 
physiologic functions of the individual, the classic 
negative feedback mechanisms become operative so 
that further releasing hormones from the hypo­
thalamus are held in abeyance, and the specific tropic 
hormones from the pituitary are not released until 
there is further need for additional hormones. 
In the biosynthetic defects discussed here, the 
steroid end products necessary for physiological 
function are not formed in optimum amounts. This 
triggers release of releasing factors from the 
hypothalamus which in turn causes secretion of the 
tropic hormones from the pituitary. Next, stimula­
tion of the target glands (adrenal and/or gonads) 
leads to excessive intermediate products being 
elaborated up to the point of the defect. Clinical 
manifestations of these disorders are due to a 
deficiency of a normal end product, an excess of in­
termediate substances with the possible peripheral 
conversion to other hormones, or usually both. In 
defects involving steps early in the biosynthetic 
pathways, the adrenals and gonads are involved. Ab­
normalities occurring later in the order of flow usual­
ly involve only one gland or the other. Important sex 
steroid precursors and weak androgens may be 
formed by the adrenal and converted to more potent 
androgens and even estrogens in certain of these dis­
orders. Such conversions apparently occur in the liver 
and skin and possibly other tissues. However, the 
gonads do not form glucocorticoids. 
Specific Defects. Brief descriptions of biosyn­
thetic defects will be outlined starting at the more 
15 
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reported two patients with this disorder and collected 
five additional cases. All seven died before the eighth 
2 
3 
OH 
II 
5� 
4 6 
20 
13 
16 
14 15 
7 
Cholesterol 
Fig. I-Numbering sequence for the first 21 carbon atoms in 
steroid nomenclature. Useful in locating biosynthetic steroid 
defects described in this paper. 
primitive, or early, stages of steroid biosynthesis 
and proceeding to later-stage defects. Accordingly, 
the order of presentation bears no relationship to 
relative frequency or importance of these dis­
orders. 
C-20 block with /ipoid adrenal hyperplasia 
(Desmolase deficiency CAH) (Fig. 3). Being unable 
to convert cholesterol to pregnenolone, af
f
ected in­
dividuals lack life-sustaining steroids; hence the dis­
order is fatal. The condition is of interest lo the 
gynecologist in that it supports Jost's work regarding 
virilization of the genital tracts. Being a primitive 
(early) defect, it involves steroidogenesis in the 
gonads as well as in the adrenals. The fetal testes are 
unable to form adequate androgens to virilize the 
genitalia fully, leading to genital ambiguity in genetic 
males. This is in contradistinction to the findings in 
the more common 21- and also 11-hydroxylase forms 
of congenital adrenal hyperplasia where genetic 
females are often born with ambiguous genitals. 
Cholesterol accumulates in the adrenal of affected 
individuals; hence the designation "lipoid." Theo­
retically, the treatment would be the administra­
tion of glucocorticoids and mineralocorticoids with 
the addition of appropriate sex steroids at the time of 
pubescence. Prader, Gurtner, and Siebenmann ( I, 2) 
month of life with adrenal insufficiency even though 
treatment with gluco- and mineralocorticoids had 
been employed. Although other steroid abnormalities 
may be present, it is probable that the main defect is 
in the transformation of cholesterol to pregnenolone 
(3). Early fatalities preclude this form of CAH in the 
differential diagnosis of amenorrhea, though ul-
timately a mild form of the defect with survival might 
be anticipated. 
Three (3-hydroxysteroid dehydrogenase deficiency 
(Fig. 4). Being unable to convert pregnenolone to 
progesterone, these individuals present with many of 
the features of the previously described desmolase 
deficiency. Salt loss has been a prominent feature of 
the adrenal insufficiency with the result that fatalities 
are usual. Inadequate testosterone leads to am­
biguous genitals in genetic males whereas mild 
virilization of affected females has been attributed to 
testosterone being formed from increased amounts 
of dehydroepiandrosterone (DHA) and other pre­
cursors. Since it is a primitive defect, gonadal 
steroidogenesis is also affected. In Bongiovanni's 
series (4), three females out of a total of six in­
dividuals with this form of CAH were surviving. He 
postulated a partial defect as did Kenny and his co­
workers (5). The latter authors also showed in­
creasing 3(3-hydroxysteroid dehydrogenase activity 
with increasing age. Steroid excretion patterns in 
these patients would suggest the development of 
alternate pathways which allow for survival of some 
infants. The presence of pregnenetetrol (with a 
hydroxyl group at C 21) suggests the ability of 17-
hydroxylase and 21-hydroxylase to act on this 
"primitive" molecule (6). This compound is not ex­
creted in increased amounts in the usual 21-
hydroxylase deficiency (7). Since this enzyme also 
plays an important part in the gonadal biosynthesis 
of sex hormones (6), its absence would necessitate 
substitutional sex-hormone therapy at pubescence. 
Obviously sterility can be anticipated. 
Seventeen cx-hydroxylase defect (Biglieri syn­
drome) (8) (Fig. 5). This being a primitive block, 
the gonads and adrenals are involved. Absence of 
adequate sex steroids leads to hypogonadism and 
elevated gonadotropins. The elevated levels of desoxy­
corticosterone (DOC) and. corticosterone lead to 
hypokalemic alkalosis and hypertension, thus turning 
off the renin-angiotensin mechanism with resultant 
low or absent aldoslerone. This defect is clinically ex-
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(cortisol) plasma levels are modulated by negative feedback influence or the I I-hydroxyl group on the hypothalamus and in turn its releasing 
factor for ACTH. The major sex steroids. testosterone and the estrogen,. typified by cstradiol. arc produced from adrenal DHA and 
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pressed in the genetic female by hypertension and the 
absence of puberty. In addition to the elevated 
gonadotropins, blood progesterone is high. In the 
genetic male, ambiguous genitalia and absence of 
puberty result from the inability to make either an­
drogens or estrogens; hence it is a cause of male 
pseudohermaphroditism (9). This syndrome in 
genetic females is similar to the feminizing testicular 
syndrome in the absence of secondary sex hair, bu! 
differs in that breast development is absent and 
hypertension is present. The treatment in females is 
adequate substitutional therapy with glucocorticoids. 
Preference is given to one without significant 
mineralocorticoid activity; for example, prednisone. 
Addition of sex steroids at pubescence is indicated, 
but infertility can be expected. It would appear that 
these patients could be monitored for effectiveness of 
therapy by the measurement of plasma progesterone. 
Simple uiri/izing congeniwl adrenal hyperplasia 
(mild 21-hydroxylase defect) (Fig. 6). Being unable to 
form optimal amounts of cortisol and corticosterone, 
these individuals exhibit augmented ACTH produc­
tion which leads to shunting towards the androgen 
pathway and ultimate virilization. Aldosterone and 
cortisol (hydrocortisone) are formed in suboptimal 
amounts so tha< overt adrenal insufficiency may not 
be necessarily manifes< (10, 11). The majority of fe­
male patients will have exhibited considerable evi-
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dence of virilization and usually sexual ambiguity at 
birth. leading to prompt diagnosis and treat111ent. In 
the afTected male. however. the external genitalia 
are nor111al and the diagnosis of CAH is therefore 
less obvious. This doubtless accounts for the pre­
do111inance of the disorder in females: that is. 111ales 
may die of undiagnosed hypoadrenalis111. 
Diagnosis and treatment depend largely on sup­
pressibility of the hyperactive hypothalamic-pituitary­
adrenal axis by exogenous administration or 
11-hydroxylated glucocorticoids. Androgens are elt:­
vated in plasma and urine. Estrogen excretion may 
be elevated in these individuals ( 12. 13 ). Such es-
trogenic activity is not clinically manifest. Pre­
sumably. the excessive androgens effectively over­
ride the estrogenic activity. Most investigators have 
held that urinary gonadotropins are suppressed by 
the excessive androgens ( 13. 14). However. Stevens 
and Goldzieher ( 15) found detectable and often adult 
levels of gonadotropins in 4 of 5 children with 
CA H and variable levels in adults. Steroid suppressive 
therapy led to a fall of FSH in 3 of6 patients whereas 
LH was unchanged in 5 and rose in 2. suggesting that 
co111pensatory pituitary hyperactivity in CAH is not 
limited to the pituitary adrenal mechanism but has 
repercussions in gonadotropin regulation as well. In 
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any event. once adequate suppressive therapy is in­
stituted. postpubertal females rapidly feminize and 
become ovulatory. 
Diagnosis can be suspected on the basis or 
baseline urinary 17-ketosteroids ( 17-KS). Normal 
adult females ordinarily have values between 2 and 12 
mg/24 hours. Patients with obesity. stress situations. 
essential and familial hirsutism or Stein-Leventhal 
syndro111e may have levels to 25 or even 30 mg/24 
hours whereas patients with CAH usually will have 
baseline values on the order or 50 111g/24 hours. 
Patients with adrenal adenomas ordinarily will have 
values of approximately 100 mg. and patients with 
virilizing adrenal carcinomas will have values or 200 
0 " 
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·Acetate" 
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CHOLESTEROL 
C• O 
111g or up. The degradation 111etabolite of 17 hydroxy­
progesterone ( I 70H-P). pregnanetriol, was found to 
be elevated in the urine of these patients and has been 
used for years to conf-irm the diagnosis and to 
monitor therapy. Most laboratories report normal 
values in adult females to be 4 mg or less per 24 
hours. Patients with CAH have values from modestly 
above 4 mg up to manyfold this level. The sup­
pressibility of this steroid as well as 17-KS by 2 mg of 
dexamethasone every 6 hours for two days proves the 
ACTH dependence of the disorder and differentiates 
it from the autonomous virilizing adenomas and car­
cinomas ( 16). However. it appears that pregnanetriol 
is not a primary intermediate in the formation of an-
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drogens (17) suggesting that the major pathway is 
through DHA and androstendione. Although 170H-P 
has been known to be elevated in this disorder for 
years (18). its measurement as a practical matter has 
been of more recent vintage ( 19, 20). The bother and 
inaccuracy of collection of 24-hour urine specimens 
for steroid assays has led to the measurement or 
plasma I 70H-P, progesterone, and testosterone in 
diagnosing and monitoring these patients. Lippe and 
co-workers point out multiple factors that may affect 
serum steroid determinations (21 ): hence they suggest 
that where virilization is a prominent feature in 
amenorrheic women, long-term adrenal suppression 
tests with measurement of several plasma steroids 
(for example. I 70H-P and testosterone) be utilized. 
Normal adult patients ordinarily have plasma I 70H-P 
levels of up to 200-400 ng% whereas patients with 
CA H and blocks of C-21 or C-11 hydroxylation will 
have levels severalfold that amount when untreated 
or if out of control (for example. 1-4 µg%) (19). 
A subvariant of the mild 21-hydroxylase de­
ficiency is that of the postnatal onset of the dis­
order. Sporadic cases have been reported (22. 23. 24) 
and described. It would appear that these individuals 
have a milder form of the disorder which becomes 
manifest only upon their being stressed. 
Other subvariants of the 21-hydroxylation 
deficiency include periodic fever in association with 
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elevated plasma etiocholanolone (25) and "late" 
sodium Joss (26). Hypoglycemia probably is not a 
separate subvariant but a manifestation of hypo­
adrenalism. 
Severe 21-hydroxylase defect (salt-losing con­
genital adrenal hyperplasia) (Fig. 7). This variant 
of the 21-hydroxylase defect is more complete so 
that a deficiency of mineralocorticoids including 
aldosterone exists. Shunting to the androgenic 
pathway is also present leading to virilization. The 
defect. being of more profound degree, leads to even 
higher ACTH levels than in the simple virilization 
syndrome so that hyperpigmentation may ensue and 
indeed has been used as a clinical sign in addition to 
II 
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·Acetate" 
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CHOL ESTEROL 
steroid assays in the monitoring of therapy. 
Diagnosis is the same as with the mild form, but 
treatment differs. In addition to suppressive therapy 
with a glucocorticoid, a mineralocorticoid and often 
salt supplementation are necessary. It has been 
suggested that different 21-hydroxylation defects may 
exist in the salt losers as opposed to the nonsalt losers 
(27). 
Eleven-hydroxylase deficiency (hypertensive con­
genital adrenal hyperplasia) (Fig. 8). In addition to the 
shunting along the androgenic metabolic pathway as 
in the 21-hydroxylase defects, the mineralocorticoid, 
DOC, accumulates, leading to salt retention and 
hypertension. These patients also frequently pigment 
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precocity and pseudohermaphroditism in female infants. 
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Fig. 7-Severe 21-hydroxylase defect. Virilization findings similar to the mild form but additionally salt loss occurs due to the mineralocor­
ticoid deficiency including aldosterone. 
from the excessive ACTH activity. Clinically, these 
patients present as the 11-hydroxylase patients except 
for hypertension and salt retention. Diagnosis can 
be suspected on the basis of hypertension. Biochemi­
cal confirmation is by the finding of elevated levels of 
tetrahydro-S (the degradation product of 11-desoxy­
cortisol) in the urine. More specific radioimmuno­
assays for DOC and 11-desoxycortisol may simplify 
diagnosis in the future. 
Late onset of this disorder has also been 
reported (28, 29). Zachmann and co-workers exten­
sively studied an infant girl with an 11-hydroxylase 
deficiency who was normotensive and had normal 
levels of DOC though compound S was excessively 
high. This suggested to them a selected inhibition of 
the 11/3-hydroxylation of I 7a-hydroxylated steroids 
(30). 
Eigh1een-hydroxy/ase dehydrogenase defec1 (Fig. 9). 
Ulick (31) described this disorder accompanied by 
low aldosterone resulting in low serum sodium. hi�h 
potassium, dehydration, hypotension, high renin ac­
tivity, and elevated levels of hydroxycorticosterone. 
This disorder should not enter into the differential 
diagnosis of amenorrhea and the virilizing congenital 
adrenal hyperplasias. 
Seven1ee11 /3-hydroxysferoid dehydrogenase de­
feel (deficienf 1es1icu/ar J 7-ke1os1eroid reduc1ase ac­
livity) (Fig. 10). Goebelsmann and co-workers (32) 
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described a 46-year-old married phenotypic female 
with clitoral enlargement, hirsutism, breast develop­
ment, and a blind vaginal pouch. Chromosomal 
karyotype was 46 X Y. Abdominal testes were re­
moved. Prior to operation, testosterone was at low 
normal male levels, though considerably above female 
levels. Urinary 17-KS were 33 mg/24 hours. The find­
ing of androstenedione of 1.02 µg/ 100 ml (being ten­
fold above normal male levels) suggested testicular 
I 7JJ-hydroxysteroid dehydrogenase deficiency. More 
recently, Givens and associates (33) described two 
additional patients (sisters) with primary amenor­
rhea. hirsutism. clitoral enlargement, 46 XY karyo­
type. but lacking breast development. They, too, 
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found grossly elevated androstenedione levels along 
with elevated urinary 17-KS and plasma estrone, but 
subnormal amounts of testosterone and estradiol. In 
vitro incubation of testicular tissue from their sec­
ond case confirmed a partial defect in testicular 17-
KS reductase activity and documented increased 3JJ­
hydroxysteroid dehydrogenase activity. They felt that 
failure of breast development was probably due to 
lower estrogen levels than in previously reported 
cases. Accordingly. when one finds elevated 17-KS in 
an amenorrheic individual, further delineation or 
the defect by steroid biochemical assays seems 
warranted. Indeed, such investigations may show the 
Reifenstein syndrome as well as other forms of male 
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accumulation of mineralocorticoids-principally desoxycorticostcronc. 
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pseudohermaphroditism to be due to this disorder of 
steroid biosynthesis. 
Stein-Leventhal syndrome (Fig. 11 ). Early 
workers dealing with in vitro studies showed an ac­
cumulation of DHA and testosterone in incubation 
studies on ovarian tissue from patients with this syn­
drome. These studies suggested a partial defect in 
the aromatizing enzyme to convert testosterone 
to estradiol as well as an inadequacy of 3/3-ol 
dehydrogenase activity. However, such observations 
were not interpreted to imply the uniform existence 
of invariable, all-or-none enzyme defects in the 
polycystic ovarian tissue (34). Accumulating evidence 
would suggest, however. that the issue is much more 
complex. Probably there are patients now classed 
with this syndrome whose disease primarily resides in 
the adrenal cortex. others who have primarily an 
ovarian defect: but the majority have a defect in 
hypothalamic function. Accordingly. it is felt that 
there is no such neat demonstration of a consistent 
biochemical defect as outlined in Figure 11 in spite of 
early works suggesting such. 
Case Presentations. Post-pubertal simple viriliza­
tion. Patient M.S.H .. Duke Unit #5-59154 (Fig. 12). 
A 17-year-old female was seen on referral November 
I, I 961. with defeminization. Menarche was at 11 
years with regular menses for two years. At age 13. 
the patient had mumps and measles during a two-
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week period. Infrequent and scant menses. averaging 
one per year followed. Acne and hirsutism steadily 
progressed after age 11. Loss of scalp hair had 
progressed for 5 months. Patient was said to be the 
product of a normal term delivery, though she was 
adopted. Pertinent laboratory findings are noted in 
Table I. Two rest days intervened between the 
ACTH. metapyrone, and dexamethasone tests. Sup­
pressive therapy was started, and the patient had an 
ovulatory spontaneous menstrual period 6 weeks 
later proved by endometrial biopsy. She was mar­
ried, and while on suppressive therapy. delivered 
,pontaneously on January I, 196 7. under pudenda! 
,lock anesthesia, a 5 lb. 8 oz. normal male infant 
CH, 
I 
C=O 
and on November 21, 1968, a 6 lb. 15 oz. normal 
female infant by Dr. William A. Peters. Her pelvis 
was normal by x-ray pelvimetry. During each de­
livery, the patient was supported by parenteral 
hydrocortisone, and her oral glucocorticoid was 
doubled then gradually tapered to maintenance level 
during the immediate puerperium. In that the 
patient appeared so normal and was cycling spon­
taneously, gl ucocorticoid therapy was discontinued 
in September 1969. She has continued to have 
cyclic menses without evidence of virilization. Dur­
ing the past year. her urinary 17-KS were 13.7 
mg/24 hrs on two occasions, and her 17-hydroxy­
corticosteroids (I 70H-CS) 2.9 and 4.3 mg/24 hours. 
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normal levels while achieving low normal testosterone. Reported in male pseudohermaphrodites. hence a cons,derauon in d1fferent1al 
diagnosis from common forms of CAH. 
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Co111111e111. Postnatal virilization of the female is 
more commonly due to an autonomous tumor or in­
gestion of hormones than due to the postnatal (ac­
quired) form of congenital adrenal hyperplasia. 
However. ready suppressibility of this patient's 
greatly-elevated abnormal steroids bespeaks the 
nature of her disorder. Since her onset occurred after 
most. if not full. statural growth had been achieved. 
she was not stunted. nor was her pelvic capacity com­
promised. Accordingly. delivery was spontaneous. 
Her children have been assessed for the possibility of 
congenital adrenal hyperplasia. and this has been 
ruled out. The chances of offspring having the dis­
order are remote. since the prevalence of the gene for 
the disorder is on the order of I in 128 for heter­
ozygotes and I in 67.000 for the overt disease (35). 
However. the frequency will be on the increase in that 
affected individuals with proper treatment will no 
longer be sterile (36). This patient is remarkable in 
that she has remained apparently normal for a pro­
tracted period of time off of therapy in spite of a 
severe abnormality of steroidogenesis when first diag­
nosed. Her 17-KS are now upper limits of normal and 
her I 70H-CS are low bespeaking the fact that she 
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probably is just minimally compensated. However. 
she has undergone the stress of rearing two small chil­
dren and moving to Europe without decompensating. 
Accordingly. our original hypothesis or decompensa­
tion due to psychologic stress of adolescence may bt: 
questioned (37). 
Postnatal simple virilization. Patient K.S.S .. Unit 
# 61682 (Fig. 13). A 13-year-old white female was 
seen January 18. 1963. because or "virilizing syn­
drome." She was born prematurely. Development 
was normal until age 4 when pubic and axillary hair 
became apparent. Her 17-KS were elevated. and 
glucocorticoid therapy was given elsewhere for two 
years. but discontinued by the mother when 
Cushingoid features developed. These rapidly dis­
appeared. but were followed by progressive hir­
sutism. One brother had prostatic hypertrophy 
diagnosed at age 19. 
Suppressive therapy was started January 23. 
1963. and the patient was hospitalized elsewhere 
April 3. 1963. with right lower quadrant abdominal 
pain. Fifteen days later. menarche occurred and was 
followed by regular menses and rapid budding or 
breasts. Hirsutism gradually decreased. but her voice 
remained unchanged. Significant laboratory data are 
shown in Table I. Iliac crests were fused on the ab­
dominal film. With her last menstrual period in 
May 1967. and after an adequate trial of labor. 
patient was delivered by cesarean on February 5. 
1968. of a 5 lb. 7 oz. normal female. Opera-
Fig. 12-Paticnt M .S. H .. #F-59154. Normal r eminine contour and 
cndocrint: mc.!asurements existed with comcdones and racial hir­
,uti>rn. B.P. 120/70. Weight 61 kg. 
TABLE I 
Urinar� S11.:ruiJ .... 
Patient Age Therapy 17-KS 17-0H-CS 17-Kctogcnic Prcgn..inetriol 
M.S.H. 17 None 82.8 I 1.-l I). 7 9.7 
ACTH Gel 40 U IM 
q. 12hrs. X 3days 16-l.7 .ll.O I )6.6 2-l.9 
Mctapyronc 500 mg 77-l -l 1.8 128.0 -13.2 
q. 4 hrs. X 2 days 
Dexamethasone -11.8 1.-l 9.8 2.9 
0.5 mg. q. 6 hrs. X 2 days 
Dexamethasonc H 0 3.6 0.5 
2 mg. 4. 6 hrs. X 2 days 
K.S. 13 None 40.1 71.3 
Dexamethasone I 8.3 107.8 
0.5 mg q. 6 hrs. X 2 days 
Dexamethasonc 7.6 .ll.-l 
0.5 mg q. 6 hrs. X 2 days 
Dexamcthasone 5. 7 2.7 11.6 1.-l 
2 mg. q. 6 hrs. X 2 days 
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Fig. 13-Paticnl K.S.S .. # 6168�. ShO\\:,, :-.tunlcd grtl\\th. L.11..:ial hir­
sutism. and android c:-.cu1chcon. Chc:,,t \\a:,, :,,havcd prior to 
photograph� i'vl usck hypcrtroph� \\ <h pn::-.cnt and brca:-.t develop­
ment ab:-.cnt. Voice \\a:,, baritone. B.P. 150190. \\ 1:ight 55.5 !..g. 
Hcighl 152 cm. Sr,an 151 cm. LO\\Cr :-.cgmcnt 76 cm. 
tion was necessary due to a moderately con­
tracted pelvis of somewhat android configuration. 
The patient has been maintained on prednisone 5 
mg at bedtime. She continues to cycle normally. Her 
plasma I 70H-P of 216 ngo/,. plasma progesterone 
1.4 µg0!c in luteal phase with plasma estradiol 20.3 
ng%. suggest ovulation. However, her plasma tes­
tosterone persisted in the range from 80 to 120 
ng% bespeaking continuing excessive testosterone 
production. Accordingly. an additional 2.5 mg of 
prednisone is being added in the morning. 
Co111111e111. Failure to continue glucocorticoid 
therapy as prescribed by her physician led to 
premature closure of this patient's epiphyses and ul-
timate stunting from excessive sex steroids. In turn, 
this probably necessitated delivery by cesarean 
because of cephalo-pelvic disproportion. In the past, 
some patients with adrenal hyperplasia who could 
not tolerate steroid therapy have been subjected to 
adrenalectomy. However, such surgical therapy is no 
longer warranted, for proper monitoring should be 
achievable so that the disease can be brought under 
control without significant side effects from the 
medication. Hayek and associates have suggested the 
single dose of a long-acting suppressive agent at mid­
night for therapy of this disorder with good results: 
hence simplifying therapy (38). Such therapy is 
appealing and rational. However. one must use a fair­
ly long-acting steroid: therefore. oral hydrocortisone, 
the naturally occurring hormone that is missing, can 
not be utilized. Problems persist in such patients as 
this who have their sleep-wake patterns altered by 
work habits (she is a telephone operator working 
swing shifts). This may account for the need for an ad­
ditional a.111. dose. Reversibility of some signs of 
virilization occur (the patient has lost much body 
hair. though some facial shaving is still necessary). 
Rapid feminization as shown by breast development 
and ovulatory menses is to be expected once adequate 
therapy is instituted. Her hospitalizaiion was for 
suspected appendicitis. but the pain was apparently 
mittelschmerz. since she had her menarche two weeks 
later. Clitoromegaly and deep voice have persisted in 
this patient. since such changes. once they occur. do 
not reverse. Contraception in this patient. as well as 
in the first, is by intrauterine device. Estrogen­
containing oral contraceptives should be avoided 
in as much as they confound steroid monitoring of 
such patients by altering steroid binding proteins. 
This patient was found to be hypertensive when 
initially seen. raising the question of a possible 11-
hydroxylase block. However. measurement of 
tetrohydro-S showed no significant amounts of this in 
the urine. Prolonged hypertension following cessa­
tion of desoxycorticosterone therapy in CAH has 
been reported (39): however. we feel that this is 
highly unlikely in this patient. since initial therapy 
had been discontinued for almost a decade before 
she was found hypertensive. 
Pa1ie111 L. 0. T., Uni/ # 235684-5. A 38-year-old 
nulliparous obstetrical nurse was seen on referral 
because of inadequate control of adrenal hyperplasia 
while laking divided doses during the day. Some 
evidence of virilization probably was present at birth 
(clitoromegaly). though hirsutism did not become 
WILLIAMSON AND MATHUR: DEFECTS IN STEROID BIOSYNTHESIS 29 
manifest until after age 5. In 1954, the patient 
elsewhere underwent vaginoplasty, abdominal ex­
ploration, and clitoridectomy with the findings or 
follicular cyst of the ovary with occasional ova and a 
hypertrophic clitoris (5 cm.). The adrenals were 
thought normal to palpation. The patient was em­
pirically treated with Premarin® and thyroid and 
had withdrawal bleeding. All therapy was discon­
tinued in 1964, and she had spontaneous regular 
menses for one year with flow lasting 3-5 days and on 
occasion had associated cramping. Her baseline 17-
KS were 51 mg. rising to 109 with ACTH and sup­
pressing to 13.4 mg. with Decadron®. She was dis­
charged on 25 mg. cortisone per day and was later 
changed to prednisone. However, she was seen on 
referral, and her urinary pregnanetriol was 31.5 mg/ 
24 hrs. She was shaving twice daily. The patient was 
working swing shifts as a registered nurse. She was 
advised to take 5 mg. prednisone before going to bed 
and 2.5 on arising and an additional 2.5 mg during 
the day if necessary. Since institution of this therapy. 
her plasma testosterone has ranged from 16 to 28 
ng% with concomitant loss of chest and arm hair. 
though facial shaving is still needed. Her plasma 
estradiol has been between 2 and 43 ng%, though 
she has remained anovulatory while cycling. as 
shown by plasma progesterones repeatedly less than 
400 ng%. Her I 70H-P has ranged from 118 to 
496 ng%. 
Comment. Patients working swing shifts can ex­
perience considerable difficulty in controlling their 
excessive androgen production since the ACTH surge 
may come at a time when they are not receiving their 
larger dose of suppressive steroid. Also, changing 
shifts alter diurnal variation and may in itself be a 
stressful situation causing further decompensation. If 
even suppression is not obtained by giving a dose 
prior to anticipated ACTH surge, consideration of 
longer-acting injectable therapy such as utilized in in­
fants may be considered. Neither this patient, nor our 
patient undergoing cesarean, had evidence of 
classical Stein-Leventhal type ovaries, although CAH 
has been noted associated with polycystic ovaries 
(40). The thickened capsules in such patients have 
been attributed to excessive androgens. 
Patient P.B., Unit # 233484-2. A 23-year-old 
gravida II, para I, abortus O had menarche at age 12 
and cyclic menses until age 16 when she started skip­
ping menses. At age 17, she had ovarian wedge resec­
tions elsewhere with diagnosis of Stein-Leventhal 
syndrome. However, menses did not resume. She was 
seen by another physician who treated her with pred­
nisone. Menses then resumed, and the patient spon­
taneously achieved a pregnancy only to have mid­
trimester loss with prolapsed cord, intrapartum 
death, and delivery by cesarean. On physical exami­
nation, the patient had considerable facial hirsutism, 
modest clitoromegaly, but normal size ovaries. 
The patient was again studied off therapy with ele­
vated l 70H-P of 4.4 µg%. Her plasma progesterone 
was 132 ng%. With adequate suppression, plasma 
progesterone rose to 1.7 µg% (ovulatory level) and 
I 70H-P fell to 160 ng% (normal). The patient spon­
taneously resumed menses and became pregnant with 
last menstrual period November 11, 1974. On Janu­
ary 8. 1975. continuing the same dose of 5 mg 
prednisone at bedtime, her plasma testosterone was 
80 and plasma I 70H-P 137 ng%, and her plasma 
progesterone was greater than 1.6 µg%. 
Comment. Patients with congenital adrenal 
hyperplasia being adequately treated will be unable 
to have plasma or urinary estriols as an index of fetal 
well-being in as much as these steroids cross the 
placental barrier and suppress fetal-adrenal ac­
tivity-a most important source of precursors for 
pregnancy estriol. Differential suppression tests 
should be able to delineate patients with primarily 
ovarian disorders as opposed to those with primarily 
adrenal disorders and prevent unnecessary wedge 
resections in the future. 
Patient L.H.. Unit # 235525-8. A 27-year-old 
patient was seen in consultation because she had 
developed Cushingoid features as a result of being on 
prednisone for persistent amenorrhea. Menarche was 
at age 12 with an average of one cycle per year until 
age 18 when she was placed on oral contraceptives 
with regular withdrawal bleeding for three years. 
Upon discontinuance, the patient remained amenor­
rheic for one year when she was seen by a gyne­
cologist and had bilateral wedge resection of ovaries. 
She remained amenorrheic for another year except 
for scant spotting on rare occasion. The patient 
was admitted to another university center and under­
went dexamethasone suppression test with 17-KS, 
suppressing from 21 mg/24 hours to 6 mg on the 
first day of high-dose dexamethasone. She also had 
adrenal and ovarian vein catheterization, showing 
adrenal venous plasma testosterones quite elevated 
with some elevation of ovarian and peripheral 
values. She was placed on prednisone 10 mg every 
other day with spontaneous menses occurring ap­
proximately every 6-7 weeks. She then relapsed into 
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amenorrhea. Medication was discontinued for retest­
ing. and after one month off of therapy. her 
plasma I 70H-P was 1.8 µgo/o (approximately five 
to tenfold the normal values) with plasma testoster­
one 79 ng% (upper limits of normal for adult 
females in our laboratory are 60 ng%). plasma 
cortisol 10 µgo/o at 8 a.m .. plasma estradiol 24.1 
ng% (normal proliferative phase value), plasma 
progesterone 94.5 ng% (anovulatory value). On 
suppressive therapy. I 70H-P fell to 165 ng%, tes­
tosterone was 71 ng%. and plasma estradiol re­
mained at 22.9 ng% with progesterone 78 ng%. 
Stimulation with Clomid®. escalating doses to a 
maximum of 150 mg/day times five days. indicates 
the patient remains anovulatory with progesterone 
50.5 ng%. plasma estradiol 24 ng%. while 170H-P 
has remained 112 to 216 ng% during the time she 
is being maintained on p.m. suppressive prednisone. 
Commenl. This patient with a mild form of 21-
hydroxylation defect with first manifestations in post­
natal period did not achieve smooth suppression with 
alternate-day therapy. Even though nighttime 
therapy has brought about normalization of I 70H-P 
and near normal values of plasma testosterone. she 
remains anovulatory and unresponsive to Clomid"" 
at this time. In this patient, the elevation of 170H-P 
in the plasma out of proportion to the progesterone 
would indicate that her primary pathway to I 70H-P 
is through 17-hydroxy-pregnenolone rather than 
through progesterone. Also. findings would suggest 
that even though near-optimal biochemical control of 
the disorder can be achieved. fertility does not 
automatically ensue. She probably needs further sup­
pressive therapy. If optimum control is then achieved 
as shown by normal plasma testosterone. I 70H-P. 
and urinary 17-KS. then a search for other causes or 
amenorrhea are warranted, for they can be subject to 
such disorders as hypothalamic amenorrhea. 
Patieni J. L., Unit # 161059. An I I-year-old 
patient was seen in consultation after she had seen a 
group movie at school on sexual development in 
which a photograph of abnormal external genitalia 
was shown. She persisted in telling her teacher that 
she had such abnormal genitalia. Although "show 
and tell" in its fullest sense did not occur, this ex­
perience led to her being referred where the disorder 
was well characterized. She is now on suppressive 
therapy. 
Comment. Clitoromegaly of this degree, had it 
been present at birth, surely would have been 
recognized, though possibly some physicians may 
attempt to downplay its importance. However, the 
clinical course of this patient, that is, the onset of 
hirsutism and facial acne just prior to her evalua­
tion. would suggest postnatal onset of her disorder. 
Patient C. G., Unit # 172230-/. A 20-year-old 
patient had onset of virilization at age 11, and the 
diagnosis of congenital adrenal hyperplasia was made 
at a medical university well known for its large series 
of congenital adrenal hyperplasia patients. Initial 
attempts to control her here by continuing cortisone 
acetate which had been instituted elsewhere failed, 
and she was switched to prednisone in 1970. taking 
2.5 mg every eight hours. However, when seen in 
February. 1974, her 170H-P was greater than 1.4 
µgo/o. and her plasma progesterone greater than 1.6 
µgo/o. with plasma testosterone 72 ng%. She was 
anovulatory as shown by endometrial biopsy and 
basal body temperature charts. Five mg. of pred­
nisone at bedtime still failed to achieve suppression 
with plasma I 70H-P of 3.7 µgo/o, therefore, pred­
nisone has been increased to 7 .5 mg/day while sterili­
ty investigation is being pursued. 
Discussion. Differential diagnosis of congenital 
adrenal hyperplasia includes disorders of adrenal and 
gonadal origin. Rarely are such entities as Morgagni­
Stewart-Morel syndrome or Achard-Thiers syn­
drome of any importance in the differential diagnosis. 
if indeed they represent true syndromes. 
Cushing·s syndrome is readily differentiated by 
overnight dexamethasone suppression test in most 
patients and by baseline values of glucocorticoids. 
Rarely is virilization of the degree seen with CAH 
present in patients with Cushing's syndrome. Ex­
ogenous administration of virilizing hormones can 
present a problem particularly when the patient does 
not know what she has received. Anabolic steroids 
have been given in wasting diseases, osteoporosis. 
and to improve libido. The differentiation of ovarian 
hyperandrogenic syndromes including Stein­
Leventhal syndrome can generally be made on the 
basis of differential suppression tests employing 
glucocorticoids to suppress the adrenal component 
and combination estrogen-progestogen preparation 
such as Enovid"" E for the ovarian component (41. 
42). True hermaphroditism usually is not much of a 
problem since prepubescent hirsutism is not usually 
evident even though ambiguous genitalia may exist. 
Steroid assays readily differentiate the conditions. 
Occasionally, patients with gonadal dysgenesis with a 
Y stem line (usually) may present with signs or hir­
sutism and clitoromegaly. This has been particularly 
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true of patients with gonadoblastomas or Teter's 
gonocytomas III and IV. Again, steroid assays readi­
ly differentiate the condition. In patients with viriliz­
ing ovarian tumors such as an arrhenoblastoma, 
elevated androgens will not suppress with exogenous 
administration of glucocorticoids. Further, their 
urinary 17-KS are generally not of the magnitude or 
those seen with CAH. 
Summary. Enzymatic defects of adrenal and 
gonadal steroidogenesis have been described, many 
of which lead to amenorrhea and sexual ambiguity. 
Seven patients with congenital adrenal hyperplasia 
are presented who were first diagnosed at times far 
removed from the neonatal period. One such patient 
had dramatic onset of hirsutism, amenorrhea, and 
profound elevation of androgens. After suppression. 
she achieved two pregnancies, delivered. and subse­
quently has gone off therapy and continues to have 
cyclic menses in spite of borderline steroid values. 
The usefulness of a single nighttime long-acting 
glucocorticoid in achieving smooth suppression in 
patients with adrenal hyperplasia appears rational 
and is meeting with success. Diagnosis and monitor­
ing of therapy of such patients has been facilitated 
by the availability of immunoassays for 170H 
progesterone, and testosterone in lieu of urinary 17-
KS, and urinary and plasma pregnanetriol assays. 
Authors' note: Since preparation of this presenta­
tion, Sa reductase deficiency has been described in 
association with male pseudohermaphroditism. 
(Walsh et al, Familial incomplete male pseudo­
hermaphroditism, type 2, decreased dihydrotestoster­
one formation in pseudovaginal perineoscrotal hy­
pospadias, N Engl J Med 291:944-949, 1974). 
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Treatment of Amenorrhea: When Pregnancy Is 
and Is Not Desired* 
JOHN A. BOARD. M.D. 
Professor of Obstelrics and Gynecology. Medical College of Virginia. 
Hea/1h Sciences Division of Virginia Co1111nonwea/1h University. Richmond, Virginia 
We have had three discussions this afternoon 
concerning amenorrhea. and most of these have dealt 
with the diagnosis of causative conditions. I am going 
to discuss the treatment of these women. 
Whether or not the woman wishes to conceive in 
the immediate future determines the plan of treat­
ment in most cases. If conception is desired. I believe 
it should not be immediately assumed that the 
amenorrhea is the sole cause of the infertility. I would 
check patency of fallopian tubes and adequacy of the 
husband's sperm production before treating for con­
ception. Regardless of the plans for pregnancy. 
however. it should be determined whether the woman 
is merely not ovulating with adequate endogenous 
ovarian estrogen production or whether the ovula­
tory failure is associated with lack of estrogen as well. 
The former might occur if pituitary gonadotropins 
were reduced and/or the preovulatory LH surge were 
absent. The latter condition may be due to failure 
of production of pituitary gonadotropins or to meno­
pause with elevated levels of pituitary gonadotropins. 
Several brief case reports of women with 
amenorrhea will follow. In some of these. there will 
be organic disease of the extragenital endocrine 
glands such as the thyroid gland, or the adrenal 
gland, or the pituitary gland. In others, there will be 
no identifiable extragenital endocrine disease: then 
the treatment would vary depending on whether or 
not the woman wishes to become pregnant. 
Case I. This patient was a 35-year-old gravida I. 
• This is an edited transcription of a lecture presented by Dr. 
Board at the 46th Annual McGuire Lecture Series. December \ 
1974. at the Medical College of Virginia. Richmond. 
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para I. aborta O who was seen after having amenor­
rhea for six months. She had noticed tachycardia, 
sweats. and weight loss. The radioactive iodine 
uptake was 80% in 24 hours: this is much higher than 
normal for this laboratory. A diagnosis of hyper­
thyroidism was made. The patient was treated with 
radioactive iodine and had resumption of regular 
menses after the second course of treatment. She is 
not presently trying to become pregnant. 
In preparing for this talk. I was looking for in­
stances of thyroid disease that caused amenorrhea, 
and I couldn't find any where hypothyroidism was 
the etiologic factor. I am as aware as you all are of the 
thousands of women who have taken thyroid medica­
tion as treatment for amenorrhea. but in the patients· 
charts to which I had access. I could not find one 
where this was the real etiologic factor. I did find 
the following case of hyperthyroidism. 
Case 2. This was a 30-year-old gravida 11, para I 
who had had amenorrhea for two years after a spon­
taneous abortion. She had moderate hirsutism. but 
no other virilizing signs. An endometrial biopsy 
showed "resting endometrium," that is. proliferative 
glands without mitotic activity. Thyroid studies were 
normal. and two urinary 17-ketosteroid deter­
minations were moderately elevated: 16.1 and 18.1 
mg/24 hours. It was decided that this was a case of 
adrenal androgenic hyperfunction. The patient was 
initially treated with dexamethasone 2 mg three 
times a day for 2 days. followed by 0.75 mg/day 
for maintenance. Ultimately. this was reduced to 
0.5 mg/day. Under this treatment, the urinary 17-
ketosteroids fell to 2. 7 mg/24 hours. Ovulatory 
cycles began and conception occurred. 
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Case 3. This was a 26-year-old gravida 11. para 2 
who was seen because or amenorrhea and galac­
torrhea since her last delivery two years earlier. This 
patient had been worked up about a year pre­
viously elsewhere and had had normal skull x-rays. 
normal visual fields. and normal EEG. The skull 
x-rays were repeated: this time a destructive lesion 
of the sella was seen. and the visual tields had a 
bilateral defect. A transsphenoidal removal or pru­
lactin-producing pituitary adenoma was done leaving 
the remainder of the pituitary gland. Following this. 
spontaneous menses have returned and they are 
ovulatory. The visual fields have also returned tu 
normal. 
The first three cases dealt with patients who had 
organic diseases of extragenital endocrine glands. 
The remaining four cases have nu identiliable ex­
lragenital endocrine disease. 
Case 4. This was a 20-year-uld gravida O "hose 
menses began at age 13 and had occurred every 35 
days lasting 7 days until two years earlier when 
amenorrhea had begun. coinciding with the lirst year 
of college. She had a history or having received 
thyroid medication in the past although she had 
received none for the preceding year. The l"ree T, was 
1.5 mg%. a normal value. and the maturation index 
was 0/65/35. Oral medroxyprogesterone was admin­
istered. and the patient had withdrawal bleeding 
after this. An extensive investigation was not dune. 
but the medroxyprogesterone medication was con­
tinued for 3 months. After this. spontaneous 
cycles returned. 
Patients who have endogenous estrogen can 
usually be treated with only a pure progestin given at 
monthly intervals. It is unlikely that they have 
anything seriously wrong with their hypothalamic­
pituitary axis. When given an exogenous progestin at 
monthly intervals (we usually give medroxyproges­
terone for 5 days beginning al cycle day 22). 
monthly bleeding episodes usually result. Some 
women who do not want to menstruate 13 times 
a year will be given the medication two 10 rour 
limes a year. I do not think it is good for endu­
metrium to be continuously stimulated by estrogen. 
whether it is endogenous or exogenous. because ur 
the possibility of endometrial hyperplasia. and I 
think that even if the woman is not enthusiastic 
about menstruating, she should be given this medi­
cation at least several times a year. 
Case 5. This was an 18-year-old gravida O who 
had onset or menses at age 10 and who had had 
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menses every 31 days lasting 5 days until she 
entered college. Prior to this, she had experienced 
amenorrhea in the summer when she had gone 
away to camp. but the amenorrhea had ceased 
when she returned home. She had very slight 
hirsutism. and there was no withdrawal bleeding 
after medroxyprogesterone. The serum FSH and LH 
were normal. Tests of thyroid function. skull x-rays. 
and urinary 17-ketosteroids were normal. The patient 
was treated with cyclic estrogens and progestins 
(conjugated estrogens 1.25 mg daily for 21 days 
with medroxyprogesterone 10 mg daily added on 
treatment days 17-21). 
The failure of withdrawal bleeding after 
medruxyprogesterone alone in a patient who does 
have "·ithdrawal bleeding after estrogen-priming be­
fore a prugestin is given indicates lack of endo­
genous estrogen production. The group or patients 
without endogenous estrogen includes cases where 
the defect is ovarian (such as agenesis. castration. 
or premature menopause) as well as cases or pitui­
tary failure (such as that secondary to defective 
releasing factors. ablation by surgery or radiation. 
and diseases such as Sheehan·s syndrome). If this 
syndrome appears at a time when it is appropriate 
for a woman to stop menstruating. as would be the 
case if she were in her mid-40's. I don't think the 
condition necessarily needs to be treated. Certainly 
when it occurs in an 18-year-old girl. as this did. 
I believe that it is reasonable to treat with estro­
gen plus a progestin. This will result in regular 
episodes of withdrawal bleeding. 
Case 6. This was a 27-year-old gravida I. para I 
who had become pregnant the first time without 
dilliculty. but who had had amenorrhea for six years. 
She desired pregnancy. She weighed 208 pounds. had 
mild facial hirsutism. and normal adnexa. Urinary 
17-ketosteroids were 4.4 mg/24 hours. a normal 
value. The maturation index was 0/86/14: a Rubin's 
test had shown tubal patency. and a postcoital test 
had shown abundant sperm. After medroxyproges­
lerone-induced withdrawal bleeding. this patient 
was given clomiphene 50 mg daily for 5 days. and 
she promptly became pregnant in the first month 
of treatment. 
When clomiphene is used. the pregnancy rate 
will he around 30%. The incidence or ovulation is 
much greater than 30%. but every patient who shows 
evidence or ovulation does nut always become preg­
nant. This may be due to the fact that we think the 
p..:rsun is ovulating when she really is nut. All of our 
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indices for detection of ovulation are based on the 
effects of progesterone, because we know that in nor­
mal women progesterone is present and exerts its 
effect primarily after ovulation, and we assume that 
this also happens in abnormal states. I am not ab­
solutely sure that this is so, but I have no valid proof 
that it is not. Ovulation apparently is induced. or at 
least progesterone is produced, in about 70% of the 
women receiving clomiphene, but pregnancy occurs 
only in about 30%. 
Sometimes couples will want to know when is 
the best time for exposure after clomiphene to 
achieve a pregnancy. It is my practice to tell the 
patients to begin having regular intercourse about 
four days after the last tablet and to continue this un­
til the basal temperature has been up for three days. 
Clomiphene is not without side effects. Ovarian 
enlargement may occur in about 14% of patients. and 
sometimes the ovaries become quite large. but the 
problem is much less than with the agent that will be 
dis�ssed shortly. Hot flashes are the common com­
plaint that patients report. If patients are reassured 
about this and told that they are not menopausal. it 
does not seem to be a troublesome effect. The in­
stance of multiple pregnancy is increased tenfold. 
Under normal circumstances. the incidence of multi­
ple pregnancy is around I in 80: with clomiphene it 
will rise to around I in IO or I in 12. Blurring of vi­
sion may occur in around I% of patients. and when 
this occurs. it is an indication to discontinue the 
medication. Spontaneous abortion occurs at a higher 
rate than would be expected. 
Case 7. This was a 29-year-old gravida I. para I. 
aborta O who desired pregnancy and who had had 
amenorrhea for nine months when she was first seen. 
She had been on oral contraceptive medication prior 
to her first pregnancy: this had been discontinued. 
and she had conceived promptly without difficulty. 
After that pregnancy, she took combination oral con­
traceptive tablets for several years. Her other work­
up had indicated that her thyroid function was nor­
mal, that the blood FSH and LH were normal. and 
that 17-ketosteroids were also normal. Tubal patency 
and sperm production were adequate. Attempts to in­
duce ovulation with clomiphene began with a low 
dose of 50 mg daily for 5 days. This was raised 
gradually to 200 mg/day for 5 days, with chorionic 
gonadotropin added after this. This was not 
successful; then treatment with menopausal-chori­
onic gonadotropin was given according to the 
outline in Table I. 
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TABLE I 
Outline of Gonadotropin Rx 
Cervical Plasma 
lb Day Mucus Estradiol Rx 
I 0 HMG 75-75 u. 
0 HMG 150-150u. 
.1 0 HMG 150-150u. 
4 I+ HMG 150-150u. 
I+ 1.14 pg/ml HMG 150-150u. 
2+ 179 pg/ml H MG 225-225 u. 
2+ 2.17 pg/ml HMG 300-300 u. 
8 3+ 332 pg/1111 HMG 300-300 u. 
9 H 478 pg/ml HMG 300-300 u. 
10 4+ 938 pg/ml HMG 10.000u. 
II 
12 BBT down 
13 Sustained rise in BBT began. followed by menses. 
1 n such cases. one may get response to 
menopausal plus chorionic gonadotropin. The in­
stance of pregnancy with this treatment is around 
25%. This treatment is also associated with side 
effects. One has to be very careful in giving it. 
Ovarian enlargement may occur in up to 20% of the 
cases. and in extreme instances may be associated 
with acites and even plural effusions. The cysts 
may rupture. and there may be hemoperitoneum. 
The severe hyperstimulation syndrome is found to 
be associated with abdominal distention and 
hemoconcentration (because so much of the body's 
total fluid volume has gone into the abdominal 
cavity). The treatment is bedrest. intravenous fluids 
with close monitoring of electrolytes. and avoid­
ance of pelvic examinations. This can become 
serious. can lead to thrombosis. and there have been 
several deaths. The instance of multiple pregnancy 
with menopausal-chorionic gonadotropin treatment 
is 20-37%. and the instance of abortion is around 
28%: an incidence greater than would be expected 
with normal spontaneous ovulation. In one series, it 
was found that three-fourths of the multiple pregnan­
cies were twins. and one-fourth of the multiple preg­
nancies were three or more. 
There are several problems in treating women 
with gonadotropins. One wants to give enough 
medication to induce ovulation, but not so much that 
the hyperstimulation syndrome is produced. In 
this particular patient, the menopausal gonadotropin 
dosage was gradually increased until day IO when 
good cervical mucus was seen, indicating that, 
more than likely, enough medication had been. 
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given. Laboratory tests of estrogen production 
were done to determine that too much had not 
been given. In many institutions. the determination is 
of urinary estrogen. but at the Medical College or 
Virginia there is a technique whereby plasma es­
tradiol can be measured in about six hours. The 
patients have blood drawn in the morning and return 
at 4:00 p.m .. at which time the laboratory data is 
available. The aim is to reach a level or between 500 
and IOOO pg/ml of estradiol. If the level stays un­
der IOOO pg/1111. the incidence of hyperstirnulation 
syndrome is much less than if the level is higher. 
If this patient had been given another day or treat­
ment. a situation might have been created where 
hyperstimulation would have occurred. The patient 
did not become pregnant. although evidence for 
ovulation was obtained from basal temperature 
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charts. I want to emphasize this because I think this is 
a way a physician can get in trouble. One can decide 
when he has given enough estrogen by the effect on 
cervical mucus. but one cannot tell when he has given 
too much. If est radio I levels are too high, one would 
not give chorionic gonadotropin, stop the treatment, 
and try again in a month or so, giving less medi­
cation. I think to avoid serious complications in 
treating a nonlethal condition. there has to be some 
way of assessing the estrogen production from the 
stimulated ovaries. 
I have tried to illustrate the treatment for 
amenorrhea of different causes and to emphasize the 
fact that the treatment is different when the woman 
wishes or does not wish to become pregnant. I have 
also pointed out some of the hazards of the various 
methods of treatment of this condition. 
Patient Factors Limiting Success of 
Cancer Detection* 
DEAN R. GOPLERUD, M.D. 
Associate Professor of Obstetrics and Gynecology, Medical College of 
Virginia. Health Sciences Division of Virginia Commonwealth University, Richmond. Virginia 
The American College of Obstetricians and 
Gynecologists has established as one of' its goals for 
the next decade the reduction of mortality from 
breast and pelvic cancer by 50% (I). Radiation 
therapy and surgery are the main modalities of treat­
ment for most genital cancers. These modalities have 
advanced to the level of diminishing returns. lm­
munotherapy is in its infancy, and chemotherapy is 
presently used mainly for palliation and for 
prolongation of life except for a few malignancies, 
choriocarcinoma being the classic example. 
Barring a monumental breakthrough. it appears 
that any major advance in improving mortality 
statistics will be the result of early cancer detection. 
Cancer detection involves many factors. but basic 
units in the scheme include the patient, the physician 
or his representative, and the facility in which detec­
tion procedures are carried out. It is safe to assume 
that most people do not need to be convinced that 
early cancer detection is a desirable goal. Many facili­
ties exist such as physicians' offices, hospital facili­
ties, and public clinics, all of which can figure promi­
nently in cancer detection. One of the major unful­
filled objectives of cancer detection programs is the 
inclusion of all eligible patients. This requires motiva­
tion of patients in such a manner that they will seek 
out and utilize the available cancer detection facilities. 
The Papanicolaou smear and routine pelvic ex­
amination have been shown repeatedly to be simple, 
reliable, painless, and widely available. Yet, only an 
estimated 50% of the eligible women in our comm uni-
• Presented by Dr. Goplerud al the 46th Annual McGuire 
Lecture Series, December 6. 1974, al the Medical College ol' 
Virginia. Richmond. 
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ty have ever had a Pap smear. There is an even higher 
proportion of post-menopausal women who have 
never had a Pap smear. It is precisely from this pop­
ulation that we see patients who have far-advanced 
tumors of the cervix at the time of their first admis­
sion. 
What are the reasons for this apparent dis­
crepancy between the availability of the means for 
early detection and the lack of utilization? This is the 
problem I would like to explore and make some 
suggestions for improvement. 
If women are to participate in programs for early 
detection of cancer, there are several steps that must 
be taken. First, they must know about the program 
and its value. The dissemination of cancer informa­
tion is a worthwhile endeavor, but education of the 
patient takes place in different ways. Certainly the 
cancer education program of the American Cancer 
Society, our public health agencies, our medical 
societies, and universities should not be abandoned, 
but to a great extent we are preaching to the "already 
converted." The women's clubs and PTA groups that 
often sponsor education programs by the local 
Cancer Society are composed largely of women who 
are already convinced of the value of early cancer 
detection. Most gynecologists in private practice are 
very concientious about performing regular pelvic 
examinations including Pap smears on their patients. 
Commendable as this may be, the number of positive 
smears obtained in this manner is not great, and oc­
casionally one may wonder if it is worth the ef
f
ort 
and expense to do smears once or twice a year on 
women who have had several previously negative ex­
aminations. Asymptomatic women who come regu-
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larly to the private gynecologist's office are basically 
a low-risk group for the development of cervical 
cancer. 
One of the proven ways to screen patients is to 
combine screening procedures with services that the 
patients need and want. Mature women are either in 
the child-bearing years or post menopausal. We need 
to look at these groups separately. 
The sexually active young woman is likely to be 
seen in a private office or a public clinic for either 
contraception or prenatal care. At that time she is 
very likely to have a Pap smear and pelvic examina­
tion done: in fact, it would be difficult for her to 
avoid it. Consequently, these patients have cancer­
screening tests done as an ancillary service, not 
because this is their primary motivation for seeking 
care. In order to continue to get the care she wants, 
this type of patient is given return appointments and 
will have repeat examinations and smears done. 
If these young, sexually active women have an 
abnormal smear, follow-up examination is usually 
recommended. Consequently, the patients referred to 
our Anaplasia Clinic are most commonly drawn from 
this group. It is not difficult to do effective cancer 
screening if you are providing a service that patients 
desire and will seek out. 
The post-menopausal woman of 65 who comes 
in bleeding from a Stage II 1-b cancer of the cervix 
does not fall into any of the categories related to 
pregnancy. All too often she gives a history of having 
her last encounter with a physician at the time of her 
last delivery some 30 or more years previously. Why 
don't these patients come in for examination') We 
must examine the motivation and understanding of 
the medically-indigent, middle-aged, and post-meno­
pausal woman, since this is the group that has 
the greatest need for cancer screening and also shows 
the poorest utilization of cancer-screening services. 
Sociologists tell us that motivation in medically­
indigent patients is related to many factors (2, 3). 
Fear of surgery, fear of cancer, and ultimately, fear or 
death are important. The pressing problems of im­
mediate day-to-day life such as obtaining sufficient 
food, clothing, and adequate shelter often preclude 
concern for a possible future problem which could be 
prevented by such measures as cancer screening. 
Lack of knowledge about the availability of screening 
procedures and their possible significance is impor­
tant, but although patients often are aware at some 
level of these measures, they still do not take action. 
If patients are to be convinced that they should seek 
medical care when they do not have symptoms, they 
must be made aware that the disease in question can 
affect them. They must also be convinced that the dis­
ease is curable and prevention is better than treat­
ment for the active disease, even though cure is likely. 
One of the common reasons given for not seek­
ing a Pap smear is that the patient feels well and 
equates the lack of symptoms with good health. Most 
patients in this age group are aware that cancer­
screening examinations are available. However, some 
patients are afraid that if cancer is found, an opera­
tion may be recommended. In one survey, many of 
the patients interviewed felt that cancer was essential­
ly incurable and therefore there was little to be gained 
by finding out the bad news earlier than necessary. 
Other patients feel that the test may be painful or that 
they will be subjected to indignities in a clinic situa­
tion. Fear that surgery will cause some interference 
with sexual function is a common concern. These 
beliefs and attitudes have been found consistently 
in ghetto populations by numerous surveys (3). 
The woman who is asymptomatic must first 
learn about the availability of cancer screening. The 
commonly used mass media such as radio, television, 
and the press are not particularly effective in reaching 
the ghetto population which is at highest risk. These 
women are more often influenced by personal contact 
with friends and relatives and by their own personal 
experiences in health facilities (3). 
The patient should then be made aware that 
she is a possible candidate for the development of 
cancer. Subsequently, she must be convinced that 
treatment is effective and that she could benefit from 
such treatment if it were necessary. 
Utilization of services will be improved if the 
clinic facilities are located in areas close to where the 
patients live. Convenient hours must be arranged. 
This often means having clinics open in the evening. 
Finally, let us consider the woman who has 
symptoms which might logically suggest the possibili­
ty of cancer but who delays seeking care. We have 
recently attempted to interview some of the patients 
who were admitted with cancers which obviously 
have been present for long periods of time in an effort 
to learn more about the reasons why the delays oc­
curred.* Fear of learning the diagnosis and fear of the 
* (Oral communications from J. Jones, R. N., Department or 
Nursing, Medical College of Virginia Hospital, Richmond. Vir­
ginia). 
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consequences of treatment rank high on the list of 
reasons for patient delay. One nulliparous patient 
stated, "I think if I had had a baby I would almost 
have had to go to a doctor then, and maybe I would 
have continued to go after that. I guess I just have 
always been scared to go to the doctor because of 
what he might find." At this point the patient 
described some of her relatives who had died from 
malignant disease. She went on to say. "My friends 
and neighbors have been after me for a long time 
to have an examination and so had my doctor. 
I have been going to see him every three months 
for blood pressure examination. He would offer to 
do a pelvic examination each time I would go for 
my yearly physical, but I would say no. My friend 
had told me how painful the exam was and- I 
would get nervous when I went to the doctor. He 
was young and I just didn't feel right. He would ex­
amine me otherwise and I always had no problems. It 
is all my fault. If only I had listened to my friends and 
my doctor." 
Another example is that of a patient who had 
bleeding for many months before seeking medical 
attention. This patient was a very religious woman 
who felt that her faith would heal her and probably 
interpreted the presence of symptoms as some sort of 
punishment. The patient stated. "When your time 
comes to die. you must go. If the Lord had taken me 
two weeks ago I would have been ready:· There is a 
fatalistic attitude here as well as religious fervor. 
Interestingly enough. the patient underwent sur­
gery with complete removal of all visible tumor. She 
had an uneventful recovery and was assured that she 
had a good prognosis. In spite of the outcome and the 
long delay on her part, she was very reluctant to give 
any credit to the people who cared for her in the 
hospital. 
In the 1974 edition of its Manual of Standards 
for Obstetrics and Gynecologic Services in Ac­
credited Hospitals, the American College of Obste­
tricians and Gynecologists makes the following 
recommendation. "Good medical practice clearly 
warrants the establishment of cytologic screening as a 
hospital routine. It is therefore recommended that 
regardless of the service to which she is admitted, 
every female hospital patient who is age 18 or over or 
is sexually active should have a pelvic examination 
and a cervical-vaginal cytologic smear unless a 
negative smear has been recorded within a year. To 
implement this program, it is essential that hospitals 
make smears readily available and make every effort 
to encourage their routine use." 
Along this same line, there are now three states, 
New York, Illinois, and Hawaii, that have passed 
legislation making the Pap smear mandatory for all 
women who are admitted to the hospital who tit into 
the categories outlined in the ACOG recommen­
dations (4). It seems likely that similar legislation 
may be forthcoming in other states. There is no 
reason why departments of obstetrics and gynecology 
in any given hospital cannot exert pressure on the 
hospital administration and the rest of the medical 
staff to incorporate requirements such as these in 
their hospital bylaws. Certainly a voluntary action of 
this type would be more acceptable to most 
physicians than to have it forced upon them by 
legislative decree. 
The question immediately arises as to who shall 
perform these Papanicolaou smears on women who 
are admitted to services other than Gynecology. The 
nurse practitioner programs which are developing in 
several medical centers may provide one answer to 
this problem. A number of hospitals have employed 
such individuals to do routine Pap smears on all 
female admissions with good patient acceptance and 
good results. Any patient is given the opportunity to 
refuse to have a smear performed if she has some per­
sonal objection. In addition. any woman who has had 
a smear performed by her private physician within 
the year prior to admission is not required to have a 
smear done provided the cytology was negative (4 ). 
A program of this kind would not solve the en­
tire problem, but it could be a significant step in the 
right direction. Patients admitted to hospitals con­
stitute the captive population that is most accessible 
and the one over which we as physicians have the 
most control. 
Summary. Patient education is an important 
part of preventive measures and is most likely to be 
effective when provided in a health-related setting. 
Cancer-screening services are best utilized when they 
are combined with other health services that the 
patient needs or desires. Convenience of health ser­
vices such as location of clinics, convenient hours. 
and the attitude of health workers are significant fac­
tors. Captive populations such as hospitalized 
patients. inmates of institutions, individuals who 
must take employment physical examinations. etc .. 
may be utilized to achieve more complete screening 
of the population at risk. The influence of friends, 
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neighbors, and relatives can not be overestimated. 
Efforts must be made to utilize these influences in a 
positive way. Finally, all physicians are urged to push 
for routine Pap smears on female hospital admissions 
as a voluntary program in their own hospitals. 
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Radical Hysterectomy for Carcinoma of the 
Cervix* 
JOHN J. MIKUTA. M.D. 
Department of Obstetrics and Gynecology. Division of Gynecologic Oncology, 
Hospital of the University of Pennsylvania School of Medicine. University 
of Pennsylvania. Philadelphia. Pennsylvania 
Radical hysterectomy refers to the removal of 
the uterus and cervix and, in addition, to the removal 
of the upper one-half to one-third of the vagina. the 
parametria and the pelvic lymph nodes. This opera­
tion, which is commonly called the Wertheim opera­
tion. was actually first described by Clark in the 
United States and Ries in Germany. Wertheim's 
original operation for carcinoma of the cervix con­
sisted only of a partial parametrial removal and 
removal of the upper one-third of the vagina. It did 
not include pelvic lymphadenectomy or the removal 
of the lateral portions of the parametria. 
The early efforts at radical hysterectomy for cer­
vical cancer resulted in operative and surgical mor­
tality in the range of 25-75%. In 1903. when it 
became obvious that radiation therapy. available 
then only in the form of radium, was effective for the 
control of cervical cancer. clinicians abandoned the 
radical hysterectomy procedure in favor of this 
limited form of radiation. A few individuals persisted 
in performing the operation, and in I 935. the British 
gynecologist and surgeon, Victor Bonney, reported 
on 500 consecutive patients on whom he had done 
radical hysterectomy. His operative mortality was 
16%. 
In 1939, Dr. Joseph Meigs of Boston decided to 
take a second look at the radical hysterectomy 
procedure in view of some of the technical advances 
which had occurred in medicine, primarily in the 
areas of blood transfusion, anesthesia, antibacterial 
* Presented by Dr. Mikula at the 46th Annual McGuire Lec­
ture Series. December 6. 1974. at the Medical College or Virginia. 
Richmond. 
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chemotherapy. and improvement in pre and 
postoperative care. Between 1939 and 1951, Meigs 
performed I 00 consecutive radical hysterectomy 
operations without a single surgical mortality. This 
astounding feat provided the impetus in the United 
States for a revision of thinking about this procedure 
in the post-World War II era. 
Meigs also defined the advantages of utilizing 
radical hysterectomy in preference to radiation 
therapy for cervical cancer. These are as follows: 
I. There can be no tumor recurrence in the 
cervix itself. 
2. There can be no new tumor growths in the 
cervix or upper vagina. 
3. The problem of radio-resistant tumors is 
avoided. 
4. There can be no radiation injuries to the 
bowel or the bladder. 
In addition to the advantages listed by Meigs. 
two other important factors can be considered as 
helpful. The first of these is the ability to preserve 
ovarian function in young women. The incidence of 
metastasis to the ovary in a patient with early car­
cinoma of the cervix is negligible, and it is possible. 
by using radical surgery to preserve at least one 
ovary. to avoid the onset of the climacteric. The sec­
ond aspect is that the gynecologic oncologist will 
know the extent of the disease as reported to him by 
the pathologist after thorough study of the removed 
specimen. From this not only will the prognosis be 
known but also additional therapy can be considered. 
Also. there are several clinical situations in 
which. given equally available expert radiation 
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therapy and radical pelvic surgery personnel and 
facilities. one might elect a radical hysterectomy 
approach. These are as follows: 
I. Previous pelvic surgery (supravaginal or 
total hysterectomy) 
2. Presence of adnexal mass or masses. or 
previous pelvic inflammatory disease 
3. Diabetes mellitus 
4. Pregnancy 
5. Radiophobia 
Appreciating what has already been stated with 
regard to the advantages as well as the indications for 
the use of radical hysterectomy and pelvic 
lymphadenectomy. there are three significant limiting 
features: 
I. The medical condi1ion of 1he pa1ie111. This is 
primarily related to the patient's general condition. 
her age. obesity. and the presence of underlying car­
diovascular and other diseases which might inlluence 
the development of signiticant operative and 
postoperative complications. 
2. The 1ype and e.\"lenl of 1he malignancy 11·hic/1 is 
being 1rea1ed. In cervical carcinoma. one of the 
limiting factors is the extent of the disease and the 
degree of its parametrial infiltration. From a clinical 
standpoint. cancers of the cervix favorable for a 
radical hysterectomy are clinical Stage 1-a. minimal 
to moderate-siLed lesions which are 1-b. or very early 
Stage II-a or Stage 11-b tumors. More extensive local 
disease increases the probability of inadequate sur­
gery as well as the risk of cutting through the tumor 
at the time of operation. Similarly. the presence or 
any tumor which is spread beyond the pelvic area in 
the abdomen. particularly lymphatic involvement of 
the para-aortic nodes or liver. is considered a con­
traindication to radical hysterectomy approach as is 
the finding of any distant metastasis during the 
preoperative oncologic evaluation. Finally. radical 
hysterectomy may be utiliLed in patients "ho have 
minimal. central. post-radiation recurrence in which 
the lesion has not extended to the bladder and rec­
tum. This operation. under proper circumstances. is 
preferable to the more extensive and complicated 
procedure of pelvic exenteration. 
3. The auailabilily of a surgeon 10 pe1fom1 radical 
hysleree/omy. This factor in general provides the 
greatest limitation to the surgical approach. since 
during the standard gynecologic residency program. 
there is neither the time nor the experience available 
in the performance of radical pelvic surgery for the 
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resident to develop the necessary skills. Similarly, in 
the routine practice of gynecology. a physician will 
not have sufficient numbers of such patients to main­
tain his operative expertise and capability. This 
limitation is gradually being overcome by the 
development of training programs in gynecologic on­
cology which include training in the performance of 
radical pelvic procedures. The identification and 
utilization of the gynecologic oncologist who can per­
form such procedures and who limits his area of 
specialization to the treatment of gynecologic cancer 
and its problems. is now a reality. A certifying board 
in gynecologic oncology has been developed and in­
dividuals are being recognized for skill in this par­
ticular area. In addition. training programs are now 
available throughout the country for individuals 
already qualified in obstetrics and gynecology. They 
can receive additional training for two years to 
develop these skills. 
Let us turn to some of the improvements which 
have occurred in the results with radical hysterec­
tomy in the management of cervical carcinoma. As 
mentioned earlier. the operative and surgical mortali­
ty was one of the major limiting factors in this 
procedure. Since Meigs· original series. other writers 
in recent times have reported series or patients on 
whom radical hysterectomy was carried out with 
minimal mortality. The inevitable catastrophe will 
occur from time to time when the surgeon. at times 
overstepping the bounds of good judgement. under­
takes radical pelvic surgery on a patient and has an 
unfavorable result. In general. the operative and sur­
gical mortality should be in the range of 0.5%. 
Scrupulous attention must be given to the 
thorough preoperative evaluation of the patient. not 
unly from the standpoint of her disease process so 
that an operation of this type will not be attempted 
on a patient with distant metastatic disease. but also 
attention must be given to the general physical condi­
tion of the patient. primarily her cardiovascular. 
pulmonary. and renal systems. Infection of the 
urinary system must be brought under control prior 
to surgery. The operation itself must be meticulously 
carried out with the knowledge of the extent or the 
operation, the patient's condition. and possible 
complicating factors well known to a competent 
medical anesthesiologist. Careful dissection or the 
pelvis with specific care around the large vessels 
and ureters will insure a much lower incidenct: or 
significant vascular and urinary tract complications 
which are the chid" intra-operative problems. Finally. 
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careful attention to the details of postoperative care 
are essential to avoid the problems associated with 
pulmonary, bowel, and urinary areas and to reduce 
the incidence of thromboembolic phenomena in these 
patients. For more detailed descriptions of these 
areas of importance in the pre and postoperative 
care, one's attention is directed to Nelson's Atlas of 
Radical Pelvic Surgery.* 
The major problem creating morbidity with 
radical hysterectomy for cervical carcinoma is 
associated with the urinary tract. While Meigs listed 
among the advantages of radical hysterectomy the 
avoidance of radiation complications to the bowel 
and bladder, it became evident that there was a 
significant morbidity associated with these structures 
from radical hysterectomy. In reviewing all of the 
complications associated with radical hysterectomy 
at the Hospital of the University of Pennsylvania. in 
an unselected group of radical hysterectomy 
procedures, the greatest number, almost 50%, had 
complications associated with urinary tract. These 
were chiefly urinary tract infections, ureteral and 
vesical fistulas, and postoperative bladder dysfunc­
tion. 
Let us look specifically at the problem of 
uretero-vaginal fistula. The incidence of uretero­
vaginal fistula as reported by Meigs varied from 10 to 
15%. A significant improvement in the uretero­
vaginal fistula rate was reported by Green, who 
found that the incidence of this complication could 
be reduced to approximately 4% by leaving the 
urethral catheter in the bladder for a minimum of 6 
weeks following the operation. It was felt that this 
maneuver kept the ureteral bed in a more stable posi­
tion and allowed better healing and vascularization. 
In 1966, Green also described a technique of ureteral 
suspension in which the ureter is approximated by 
several sutures to the superior vesical artery from the 
origin of this vessel to the ureterovesical junction. In 
his original report, he found only one fistula in 65 
patients. This experience has been repeated in other 
centers, and it has been substantiated as an effective 
and simple method of reducing the uretero-vaginal 
fistula rate. This complication instead of being in the 
range of 10 to 15%, is now reported in the range of 
I to 2%. 
Rather than keeping the uretheral catheter in 
position in the bladder for a long period of time, it 
• James Nelson, Jr., A rlas of Radical Pelvic Surgery. 
Appleton, New York, 1969. 
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has been the practice at the Hospital of the University 
of Pennsylvania to evaluate the bladder prior to and 
after operation by the use of cystometry. A 
baseline measurement of bladder function is ob­
tained prior to surgery, and, on approximately day 9 
or 10 following surgery, a repeat cystometric evalua­
tion is carried out. Frequently the bladder will be 
found to be of the autonomous neurogenic type, 
where there is absence of the sensation of filling as 
well as failure of the bladder to accommodate to fill­
ing. If attention is not paid to this alteration in vesical 
function, the result will be overdistention and 
overflow incontinence. Generally by the 10th to 20th 
day after surgery there will be a gradual return of 
function toward normal, first with the return of the 
sensation of filling and the desire to void, and later a 
correction of the detrusor function where accom­
modation to filling and maintainance of low pressures 
develop until the patient has the proper desire to 
void. 
Other aspects aimed at reducing urinary tract 
morbidity are the reduction of infection and the 
avoidance of trauma. There must be clearance of 
preoperative urinary infection, gentle and minimal 
handling of the ureter during the procedure, with an 
effort to preserve its blood supply as much as possi­
ble. and finally pre and postoperative administration 
of appropriate systemic antibiotics. Local intravesical 
antibiotics may be utilized through a triple-lumen 
Foley catheter (Neosporinig G-U irrigant). Another 
approach is to carry out the suprapubic drainage 
technique to reduce possible contamination of the 
bladder seen so often with the use of the urethral 
catheter. 
An added factor in reduction of uretero-vaginal 
fistula is the use of techniques to reduce the collec­
tion of serum and lymph in the retroperitoneal space. 
This was originally described by the Chinese using 
the paracoccygeal route. More recently, Welch, Pratt. 
and Symmonds applied closed-suction techniques to 
the retroperitoneal area via the abdominal wall. This 
TABLE I 
Cancer of Cervix 1955-1969 Radical Hysterectomy Stage 
of Disease 
Stage 1-a 
Stage 1-b 
Stage 11-a 
Stage 11-b 
Total 
28 
62 
8 
4 
102 
44 
Stage I 
Stage II 
TABLE 2 
Radical Hysterectomy 5-yr. survival 
Cancer of Cervix HUP 1955-1969 
Total L 
90 75 
12 8 
% 
83.3 
66.6 
decreases the amount of materials which might 
become infected, reduces the possibility of 
lymphocyst formation, and also may improve the 
ability of the ureter to maintain its blood supply. The 
results associated with radical hysterectomy as 
primary treatment for cervical cancer at the Hospital 
of the University of Pennsylvania are noted in Tables 
I, 2, 3, and 4. Comparison of statistics from one 
institution to another regarding the operable stages 
of cervical cancer show that radiation and surgery 
can provide approximately the same 5-year survival. 
The surgical proponents have always had the advan­
tage. especially where absolute survival figures are 
considered, since the surgical patients are always 
better selected, usually in better medical condition, 
and more likely to survive five years. 
Finally, it is important to consider some areas 
for the future with regard to radical hysterectomy in 
the management of cervical carcinoma. First. the use 
of cytological vaginal screening is providing the 
gynecologic oncologist with younger patients who 
have an earlier disease to treat. These patients are 
very favorable surgical candidates. Second, there is 
an unanswered question regarding the management 
of patients who are found at radical hysterectomy to 
have pelvic lymph nodes involved with tumor. 
Presently most of these patients are receiving 
postoperative irradiation therapy to the pelvis. The 
advisability of combining radical surgery with radical 
radiation must not only be measured in survival 
results but also in terms of the seriousness of the com­
plications that frequently follow such combined 
therapy. Third, one might question the advisability of 
TABLE 3 
Cancer of Cervix HUP 1955-1969 
Radical Hysterectomy-All Cases 
Total L 
Stage I-a 28 24' 
Stage 1-b 62 51' 
Stage II-a 8 4 
Stage 11-b 4 4 
* one patient each group lost-considered dead 
% 
85.7 
82.3 
50.0 
100.0 
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TABLE 4 
Cancer of Cervix HUP 1955-1969 (5-yr. survival) 
Stage 
1-a 
1-b 
II-a 
11-b 
Nega1ive nodes 
L % 
24/27' 88.8 
45/50' 90.0 
3/4 75.0 
2/2 100.0 
Positive nodes 
L % 
0/1 0 
6/12 50.0 
1/4 25.0 
2/2 100.0 
* one patient in each group lost-considered dead 
abandoning the procedure when para-aortic lymph 
nodes are found to be involved with tumor. The ques­
tion which needs to be answered is whether such 
patients are better handled by carrying out the radical 
hysterectomy procedure, where technically feasible, 
and then adding pelvis and para-aortic irradiation 
postoperatively. Answers to the second and third 
problems need to be obtained, and this probably can 
best be accomplished through national cooperative 
study groups. 
Finally. if cervical cancer detection programs 
continue to increase the findings of preinvasive 
malignancy. with the eradication of invasive cervical 
cancer. one wonders whether the case load will be 
sufficient for the maintainance of large numbers of 
experts in radical pelvic surgery among gynecologic 
oncologists. Only time will answer this question. 
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Control of Endometrial Cancer 
SAUL B. GUSBERG. M.D .. D.SC. 
Professor and Chairman. Deparunent of Obstetrics and 
Gynecology. Mount Sinai Medical School. Nell' York. New 
York 
Epidemiologic studies of this disease may offer 
etiologic clues and help us recognize high-risk factors. Of 
special interest in this respect is the infrequency of en­
dometrial cancer in Asian women and the increase in its in­
cidence in migrants to Western countries. 
The definition of high-risk factors in the peri­
menopausal years and the possibility of screening them 
by ambulatory aspiration curettage could of
f
er the 
possibility of prophylactic measures that could interrupt 
the progression to invasive cancer. The recognition of en­
dometrial cancer precursors. especially adenomatous 
hyperplasia. is critical in such surveillance and can lead to 
control in the same manner that the diagnosis of cervix 
cancer precursors has contributed to the steady decline in 
mortality from that disease. 
Modern steroid metabolic technology has enabled us 
to gain significant insights into the problems of hormone 
sensitivity of endometrial cancer and offers promise of 
allowing us to make real therapeutic advances in this area. 
The recognition of adrenal androstenedione as the 
postmenopausal estrogen precursor and the techniques of 
quantifying estradiol receptor sites in target cells will be 
very important in these studies. 
The Diagnosis and Management of 
Cervical Intraepithelial Neoplasia 
RICHARD T. UPTON, CAPT MC USN 
Chairman, Department of Obstetrics and Gynecology. Naval 
Regional Medical Center, Portsmouth. Virginia 
Carcinoma of the uterine cervix continues to be a ma­
jor health problem to the women of this country. In order 
to reduce the morbidity and mortality from this preven­
table problem, it is important that we develop and utilize 
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effective techniques of early diagnosis and treatment of the 
disease in its intraepithelial stage. 
For more than two decades the Papanicolaou 
cytosmear technique has been available to clinicians as a 
screening test for cervical neoplasia. For many years the in­
dicated follow-up evaluation of abnormal Papanicolaou 
smears suggesting cervical neoplasia was to perform a cold­
knife conization biopsy of the cervix of these patients with 
abnormal cytosmears. With the increasing acceptance in re­
cent years of the colposcope as an adjunctive diagnostic 
tool. it is now possible for most clinicians to perform, or 
have performed on their patients with abnormal cerviclll 
cytosmears. a thorough colposcopic examination of the cer­
vix and vagina and to obtain directed biopsies from areas 
of abnormality as indicated by direct, magnified vision. Ex­
amination of the endocervical canal by direct vision so far 
as possible and by endocervical curettage in each case are 
important procedures in the proper evaluation of these 
patients. By these careful adjunctive diagnostic techniques. 
it is possible to definitively diagnose the degree and extent 
of virtually all cervical intraepithelial neoplastic processes. 
In the absence of neoplastic changes in the endocer­
vical curettings. those patients with biopsy diagnosis of 
varying grades of intraepithelial neoplasia are then man­
aged according to the age of the patient and the severity of 
the dysplastic process. The patients with mild or moderate 
dysplastic changes are treated with cervical cryotherapy us­
ing either freon or nitrous oxide delivered by any of several 
currently available and acceptable machines. Upwards of 
90% of these early dysplastic changes can be reversed or 
eradicated by this technique. For those patients with more 
advanced grades of dysplasia or carcinoma in situ, 
management should take into consideration their reproduc­
tive interests. Those who have no further desire for 
pregnancy may be managed by hysterectomy with preserva­
tion of normal ovaries. If conservation of childbearing 
capability is desired, then treatment with cryotherapy or 
therapeutic cold-knife conization followed by careful 
cytologic and colposcopic evaluation is in order. The preg­
nant patient with cervical intraepithelial neoplasia may be 
managed with careful colposcopic delineation of the 
magnitude and extent of the neoplastic lesion, visualization 
of 360° of normal endocervical epithelium. and assurance 
that the biopsy was taken from the most abnormal area of 
the cervix. The pregnancy may then be maintained without 
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further therapy or diagnostic efforts. vaginal delivery ac­
complished. and then careful follow-up and definitive 
management in the postpartum period carried out. 
For those patients with endocervical curettings con­
taining evidence of dysplasia or carcinoma in situ and/or 
with cervical biopsies reported as invasive carcinoma. 
definitive management appropriate to the patient and the 
staging is then carried out without conization. For those 
patients with evidence of dysplasia or carcinoma in situ 
in the endocervical curettings but with the biopsy 
diagnosis of cervical intraepithelial neoplasia. and those 
patients in whom endocervical curettings could not be 
obtained, a cold-knife conization is indicated. This may 
then be followed immediately after definitive diagnosis. 
either the same day or within 48 hours. by definitive 
management as indicated by the stage of the neoplastic dis­
ease. 
Many techniques have been used over the years for the 
treatment of cervical intraepithelial neoplastic processes. 
These include the use of varying degrees of surgical exci­
sion. radiation therapy. ultrasound, and extremes of 
temperature by either cauterization or freezing techniques. 
In recent months. the use of the Carbon Dioxide Surgical 
Laser has come under investigation as a possible means of 
colposcopically directed, precise, laser surgical excision of 
the areas of cervical epithelial abnormality. This technique 
offers considerable promise. and the preliminary studies are 
being prepared for presentation in the near future. 
The effectiveness of these forms of management. as 
briefly discussed above, are dependent upon the co­
operativeness of the patient to obtain periodic health 
evaluations. the alertness and willingness of clinicians to 
obtain at least annual cervical cytosmears on their female 
patients. and the increasing availability of the trained 
colposcopist to define and refine the adjunctive diagnostic 
techniques and precise management that more appropriate­
ly fit the patient's needs as dictated by the degree of her 
neoplastic process. 
Breast: Non-Cancerous Diseases 
JUNE 29-JUL Y 3, 1976 STRASBOURG 
4TH INTERNATIONAL SYMPOSIUM ON SENOLOGY 
European Association of Radiology ( E.A .R.) 
I. STUDY GROUPS 
(Invited lectures, Discussions) 
A. Investigation Methods 
Physical examination, Diaphanoscopy, Radiography, Thermography, Echography 
Cytology, Histology 
Biochemistry, Endocrinology 
Psychology, Computer analysis 
8. Mastopathies 
Cystic mastopathies, Galactorrhea. Discharges, ... 
Fibroadenoma, Adenosis, Fibrosis, lnvolutive States ... 
Pre-cancerous Diseases: Dysplasia, Phyllodes, Non-invading Carcinomas .... 
C. Lactation 
Maternal Suckling 
Pathology, Psychology, Sociology 
II. COMMUNICATION, CONFERENCES 
a. Topics of Study Groups A, B, C 
b. Infections, Traumatisms, Infarcts, Lipoma, Necrosis, Thrombophlebitis, .. 
Pathology of Skin, Aerola, Nipple. 
c. Malformations, Ungracefulness, Amazonism, ... 
Plastic Surgery 
d. Breast Pathology in Man, Androgyny 
{Continued on page 51) 
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how big a dose will now 
bring relie£if it is a narcotic? 
"Tolerance is an ever-present hazard to continued 
use of narcotics .... The very first dose diminishes the 
effects of subsequent doses."1 And, as increasing 
amounts of narcotics are required to control pain, dis-
tressing adverse effects-lethargy, hypotension, con­
stipation, etc. -can needlessly debi I itate the patient. 
l.Sadove, M. S.: A look at narcotic and non-narcotic analgesics, Postgrad. 
Med. 49,102, June 1971. 
how big a dose will now 
bring relief if it is Talwin? 
Chances are, the same 50 mg. Talwin Tablet you 
prescribe originally will continue to provide good pain 
relief. Talwin can be compared to codeine in anal­
gesic efficacy: one 50 mg. tablet appears equivalent 
in analgesic effect to 60 mg. (1 gr.) of codeine. How­
ever, patients receiving Talwi n Tablets for prolonged 
periods face fewer of the consequences you've come 
to expect with narcotics. There should be fewer 
"adverse effects" on her way of life. 
Tolerance rare: Tolerance to the analgesic effect of 
Talwin Tablets is rare. 
Dependence rare: During three years of wide clinical use, there 
have been a few reports of dependence and of withdrawal symp­
toms with orally administered Ta/win. Patients with a history 
of drug dependence should be under close supervision while 
receiving Ta/win orally. 
In prescribing Ta/win for chronic use, the physician should 
take precautions to avoid increases in dose by the patient and 
to prevent the use of the drug in anticipation of pain rather 
than for the relief of pain.* 
Generally well tolerated by most patients•: Infrequently causes 
decrease in blood pressure or tachycardia; rarely causes respi­
ratory depression or urinary retention; seldom causes di�rrhea 
or constipation. Acute, transient CNS effects, describe.d 1n product information on following page, have occurred in rare 
instances following the use of Talwin Tablets. If dizziness, 
lightheadedness nausea or vomiting are encountered, these 
effects may dec(ease or disappear after the first few doses. 
•see important product information. on next page for ad�erse reactions, patient 
selection, prescribing and precautionary recommendat1ons. 
in chronic pain 
of moderate to severe intensity 
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Chances are, the same 50 mg. Talwin Tablet you 
prescribe originally will continue to provide good pain 
relief. Talwin can be compared to codeine in anal­
gesic efficacy: one 50 mg. tablet appears equivalent 
in analgesic effect to 60 mg. ( 1 gr.) of codeine. How­
ever, patients receiving Talwin Tablets for prolonged 
periods face fewer of the consequences you've come 
to expect with narcotics. There should be fewer 
"adverse effects" on her way of life. 
Tolerance rare: Tolerance to the analgesic effect of 
Talwin Tablets is rare. 
Dependence rare: During three years of wide clinical use, there 
have been a few reports of dependence and of withdrawal symp­
toms with orally administered Ta/win. Patients with a history 
of drug dependence should be under close supervision while 
receiving Ta/win orally. 
In prescribing Ta/win for chronic use, the physician should 
take precautions to avoid increases in dose by the patient and 
to prevent the use of the drug in anticipation of pain rather 
than for the relief of pain.* 
Generally well tolerated by most patients•: Infrequently causes 
decrease in blood pressure or tachycardia; rarely causes respi­
ratory depression or urinary retention; seldom causes diarrhea 
or constipation. Acute, transient CNS effects, described in 
product information on following page, have occurred in rare 
instances following the use of Talwin Tablets. If dizziness, 
lightheadedness, nausea or vomiting are encountered, these 
effects may decrease or disappear after the first few doses. 
•see important product information on next page for adverse reactions, patient 
selection, prescribing and precautionary recommendations. 
in chronic pain 
of moderate to severe intensity 
TalMn::.:1. 
Pentazoc�!!!! 
in chronic 
pain of 
111oderate to 
severe 
intensity 
Talwin® Tablets brand of pentazocine (as hydrochloride) 
Analgesic for Oral Use 
Indication: For the relief of moderate to severe pain. 
Contraindication: Talwin should not be administered to patients 
who are hypersensitive to it. 
Warnings: Drug Dependence. There have been instances of psy­
chological and physical dependence on parenteral Ta/win in pa­
tients with a history of drug abuse and, rarely, in patients without 
such a history. Abrupt discontinuance following the extended use 
of parenteral Ta/win has resulted in withdrawal symptoms. There 
have been a few reports of dependence and of withdrawal symp­
toms with orally administered Ta/win. Patients with a history of 
drug dependence should be under close supervision while receiv­
ing Ta/win orally. 
In prescribing Ta/win for chronic use, the physician should take 
precautions to avoid increases in dose by the patient and to pre­
vent the use of the drug in anticipation of pain rather than for the 
relief of pain. 
Head Injury and Increased lntracrania/ Pressure. The respiratory 
depressant effects of Talwin and its potential for elevating cerebro­
sp,nal fluid pressure may be markedly exaggerated in the pres­
ence of head injury, other intracranial lesions, or a preexisting 
increase in intracranial pressure. Furthermore, Talwin can pro­
duce effects which may obscure the clinical course of patients 
with head injuries. In such patients, Talwin must be used with 
extreme caution and only if its use is deemed essential. 
Usage in Pregnancy. Safe use of Talwin during pregnancy (other 
than labor) has not been established. Animal reproduction studies 
have not demonstrated teratogenic or embryotoxic effects. How­
ever, Talwin should be administered to pregnant patients (other 
than labor) only when, in the judgment of the physician, the po­
tential benefits outweigh the possible hazards. Patients receiving 
Talwin during labor have experienced no adverse effects other 
.than those that occur with commonly used analgesics. Talwin 
should be used with caution in women delivering premature 
infants. 
Acute CNS Manifestations. Patients receiving therapeutic doses 
of Talw1n have experienced, in rare instances, hallucinations (usu­
ally. visual), disorientation, and confusion which have cleared 
sportaneously within a period of hours. The mechanism of this 
.reacticin. is n.ot known. Such patients should be very closely ob­served and vital signs checked. If the drug is reinstituted it should 
be done with caution since the acute CNS manifestations may recur. 
Usage in Children. Because clinical experience in children under 
12 years of age is limited, administration of Talwin in this age 
group 1s not recommended. 
Ambulatory Patients. Since sedation, dizziness, and occasional 
euphoria have been noted, ambulatory patients should be warned 
not to operate machinery, drive cars, or unnecessarily expose 
themselves to hazards. 
Precautions: Certain Respiratory Conditions. Although respiratory 
depression has rarely been reported after oral administration of 
Talw1n, the drug should .be administered with caution to patients w.1th respiratory depression from any cause, severely limited res­
piratory reserve, severe bronchial asthma and other obstructive 
respiratory conditions, or cyanosis. 
Impaired Renal or Hepatic Function. Decreased metabolism of the 
drug by t.he liver. in extensive liver disease may predispose to acc.entuat1on of side effects. Al.though laboratory tests have not indicated that Talw1n causes or !ncreases renal or hepatic impair­
ment, the. dru& should be administered with caution to patients with such impairment . 
Myocardial Infarction. As . with all drugs, Talwin should be used with caution 1n patients with myocardial infarction who have nau­
sea or vomiting. 
Biliary Surgery. Until further experience is gained with the effects 
of Talwin on the sphincter of Oddi, the drug should be used w 
caution in patients about to undergo surgery of the biliary tr, 
Patients Receiving Narcotics. Talwin is a mild narcotic antagori 
Some patients previously given narcotics, including methadone' 
the daily treatment of narcotic dependence, have experier., 
withdrawal symptoms after receiving Talwin. 
CNS Effect. Caution should be used when Talwin is administeic 
to patients prone to seizures; seizures have occurred in a fews�. 
patients in association with the use of Talwin although no ca[ 
and effect relationship has been established. 
Adverse Reactions: Reactions reported after oral administration 
Talwin include gastrointestinal: nausea, vomiting: infrequen· 
constipation; and rarely abdominal distress, anorexia, diarrhe· 
CNS effects: dizziness, lightheadedness, sedation, euphoria, he; 
ache; infrequently weakness, disturbed dreams insomnia SJ 
cope, visual blurring and focusing difficulty, hailucinations (Sf 
Acute CNS Manifestations under WARNINGS); and rarely trem; 
irritability, excitement, tinnitus. Autonomic: sweating; infreque� 
flushing; and rarely chills. Allergic: infrequently rash; and rare 
urticaria, edema of the face. Cardiovascular: infrequently di 
crease in blood pressure, tachycardia. Hematologic: rarely di 
pression of white blood cells (especially granulocytes), usua 
rev.ersible and usually associated with diseases or other dru, which am. known to cause such changes, moderate transi�· eosinoph1l1a . . Other: rarely respiratory depression, urinary ret� t1on, toxic epidermal necrolysis. 
Dosage and Administration: Adults. The usual initial adult dose 
1 tablet (50 mg.) every three or four hours. This may be increase 
to 2 tablets (100 mg.) when needed. Total daily dosage should r1 
exceed 600 mg. 
When antiinflammatory or antipyretic effects are desired in add 
t1on to analgesia, aspirin can be administered concomitantly wit 
Talwin. 
Children Under 12 Years of Age. Since clinical experience in cli 
dren under 12 years of age is limited, administration of Tai� 
in this age group is not recommended. 
Dura_tion of Therapy. Patients with chronic pain who have receive 
Talw1n orally for prolonged periods have not experienced witt 
drawal symptoms even when administration was abruptly discor 
tinued (see WARNINGS). No tolerance to the analgesic effect ha 
been observed. Laboratory tests of blood and urine and of liver ari: 
kidney function have revealed no significant abnormalities afte 
prolonged administration of Talwin. 
Overdosage: Manifestations. Clinical experience with Talwin ove1 
dosage has been insufficient to define the signs of this conditioo 
Treatment. Oxygen, intravenous fluids, vasopressors, and othe­
support1ve measures should be employed as indicated. Assistec 
or controlled ventilation should also be considered. Althougl 
nalorph1ne an.d levallorphan are not effective antidotes for respira tory . depression due to overdosage or unusual sensitivity tc 
Talw1n, paren.teral na.loxone (Narcan®, available through En · Laboratories) 1s a spec1f1c and effective antagonist. 
Talwin 1s not subJect to narcotic controls. 
How.Supplied: Tablets, peach color, scored. Each tablet contains 
Talw1n (brand of pentazocine) as hydrochloride equivalent lo 
50 mg. base. Bottles of 100. 
Winthrop Laboratories, New York, N.Y. 10016 @�1t1l 
SO mg. 'lablets 
Talwin® 
brand of • 
I pentazoc1ne cas hydrochloride) (1623MI 
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e. Computer Analysis, Nomenclatures, Codifications, 
f. Comparative Psychology, Veterinary Art, Ethology 
g. Breast Functions (maternity, sexuality, aesthetics): arts, literature, fashion, history, ... 
h. Miscellaneous 
III. POST-UNIVERSITY TEACHING 
(Pre-Symposium Meetings on techniques and all applications) 
I. Journees Nationales on EC HOG RA PHY 
(French Society of Echography) 
June 28-29, 1976 
2. Post-University Courses on THERMOGRAPHY 
(European Association ofThermography) 
June 28, 1976 
3. Post-University Courses on XEROGRAPHY 
June 28, 1976 
IV. SCIENTIFIC EXHIBITION 
V. TECHNICAL EXHIBITION 
Simultaneous Translation: English, French, and German, in all rooms. 
Program and Information: 
SYMPOSIUM SEIN 1976-PROF. CH. GROS 
PALAIS DES CONGRES 
67 STRASBOURG-FRANCE 
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A service to medical education from A. H. Robins: 
l
�
es
::::.. 
Excerpted from Volume 2 
ofthe
G
.I. 
Series 
on physical examination 
of the abdomen· 
Normally palpable organs: 
the edge of the liver descending, 
on inspiration, below the costal 
margin (A): the lower pole of the 
right kidney (BJ, the abdominal 
aorta (CJ; the descending colon 
and the sigmoid (DJ: the ascend­
ing colon (El: and occasionally 
the bladder (though rising of 
this organ beyond the pubis 
does not necessarily 1nd1cate 
disease) 
Impossible to outline unless 
diseased. distended or enlarged 
the gallbladder. pancreas. 
stomach. small intestine . trans­
verse colon and spleen 
The A H Robins G 1 Series consists of six book­
lets. designed to provide a Quick yet comprehen· 
s1ve review of basic procedures and practices in 
G I medicine w11h particular emphasis on the 
phys1catexam1na11on as performed 1n !he office or ... 
at bedside If you have teaching respons1b1l1t1es. 
hmlled Quan1111es are available Pan 1 lnspect,on 
Part 2 Pa/pat1on. Pan 3 Percuss,on. Pan 4 Auscultation. Part 5 
Abdominal Pam and Part 6 01fferent1al Diagnosis of Abdominal 
Disorders. Wnte to The Medical Department A H Robins Company 
1407 Cummings Dnve. Richmond Virginia 23220 
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each tablet. 
capsule or 5 cc 
teaspoonful 
of ehx1r 
(23% alcohol) 
3m1ne sulfate O , 037 mg 
:! sulfate O o 194 mg 
1e hydrobrom1de O 0065 mg 
,arbitat (WI gr) 16 2 mg 
g may be habtl forming) 
each 
Donna1a1 
No 2 
0 t037 mg 
O 0194 mg 
O 0065 mg. 
(1;, gr) 32 4 mg 
each 
Extenlab 
03111 mg 
0.0582 mg 
0 0195mg 
(% gr.) 48 6 mg 
• 
Brief summary. Adverse Reactions. Blurring of v1s1on. dry mouth, 
d1fl1cult urination. and flushing or dryness of the skin may occur 
on higher dosage levels. rarely on usual dosage Contra1nd1ca-
11ons Glaucoma: renal or hepatic disease. obstructive uropathy 
(for example. bladder neck obstruction due to prostat1c hyper­
trophy). or hypersens1t1v1ty to any of the ingredients 
A·H·ROBI NS A H Robins Company R1ct1mond Wg1n1a 23220 
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(:Y. gr.) 48 6 mg 
• 
Brief summary. Adverse Reactions Blurring of vision. dry mouth. 
d1ff1cult urination. and flushing or dryness of the skin may occur 
on higher dosage levels. rarely on usual dosage. Contraind1ca­
t1ons Glaucoma: renal or hepatic disease obstructive uropathy 
(for example, bladder neck obstruction due to prostat1c hyper­
trophy). or hypersens1t1v1ty 10 any of the ingredients 
A·H·ROBI NS A H Robins Company. Richmond. Virg,rna 23220 
netOre Prescribmk, please consult 
complete product information, a sum-
mary of which follows:. Indications: Tension and anxiety 
states, somatic complaints which are 
concomitants of emotional factors; psy­
choneurotic states manifested by tension, 
anxiety, apprehension, fatigue, depres-. sive symptoms or agitation; symptoniat1c 
relief of acute agitation, tremor, delirium 
tremens and hallucinosis due to acute 
alcohol withdrawal; adjunctively in skele­
tal muscle spasm due to reflex spasm to 
local pathology, spasticity caused by . upper motor neuron disorders, athetos1s, 
stiff-man syndrome, convulsive disorders 
(not for sole therapy). 
Contraindicated: Known hypersensi­
tivity to the drug. Children under 6 
months of age. Acute narrow angle glau­
coma; may be used in patients with open 
angle glaucoma who are receiving appro­
priate therapy. 
Warnings: Not of value in psychotic 
patients. Caution against hazardous 
occupations requiring complete mental 
alertness. When used adjunctively in con­
vulsive disorders, possibility of increase 
in frequency and/ or severity of grand mal 
seizures may require increased dosage of 
standard anticonvulsant medication; 
abrupt withdrawal may be associated 
with temporary increase in frequency 
and/ or severity of seizures. Advise 
against simultaneous ingestion of alcohol 
and other CNS depressants. Withdrawal 
symptoms (similar to those with barbitu­
rates and alcohol) have occurred follow­
ing abrupt discontinuance (convulsions, 
tremor, abdominal and muscle cramps, 
vomiting and sweating). Keep addiction­
prone individuals under careful surveil­
lance because of their predisposition to 
habituation and dependence. In preg­
nancy, lactation or women of childbearing 
age, weigh potential benefit against 
possible hazard. 
Precautions: If combined with other 
psychotropics or anticonvulsants, con­
sider carefully pharmacology of agents 
employed; drugs such as phenothiazines, 
narcotics, barbiturates, MAO inhibitors 
and other antidepressants may potentiate 
its action. Usual precautions indicated in 
patients severely depressed, or with latent 
depression, or with suicidal tendencies. 
Observe usual precautions in impaired 
renal or hepatic function. Limit dosage to 
smallest effective amount in elderly and 
debilitated to preclude ataxia or over­
sedation. 
Side Effects: Drowsiness, confusion, 
diplopia, hypotension, changes in libido, 
nausea, fatigue, depression, dysarthria, 
jaundice, skin rash, ataxia, constipation, 
headache, incontinence, changes in sali­
vation, slurred speech, tremor, vertigo, 
urinary retention, blurred vision. Para, 
doxical reactions such as acute hyper­
excited states, anxiety, hallucinations, 
increased muscle spasticity, insomnia, 
rage, sleep disturbances, stimulation 
have been reported; should these occur 
discontinue drug. Isolated reports of ne�­
tropenia, jaundice; periodic blood counts 
and liver function tests advisable during 
long-term therapy. 
® Roche Laboratories 
01v1s1on ol Hoflmann·La Roche Inc 
Nutley, N.J. 07110 
When, for example, despite counseling, 
tension and anxiety continue to produce 
distressing somatic symptoms 
. Promnt action 
1s a goocl reason to 
consider Valium 
(diazepam) 
2-mg, 5-mg, 10-mg tablets 
